Podcasts about Cleveland Clinic

It's Tuesday, June 16th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Kevin Swanson and Timothy Reed Two pastors killed in Manipur State, India Two pastors -- Pastor Kenpibou and the Rev. Manu Thiumai -- and at least two others were found dead in India's Manipur State last week, reports The Christian Post. The victims of ethnic and religious violence were found with their hands tied and their bodies mutilated in this northeastern state.  The Economic Times quotes a Manipur home minister who described the killings as “a heinous crime against humanity.”  74% of Israelis support sexual perversion today The Jerusalem Post reports that more than 100,000 persons participated in this year's so-called “gay pride” parade in Tel Aviv, Israel. A new study conducted by the Israel Institute for Gender and LGBT Studies found that 74% of Israel supports “full and legally enforced equal rights for the LGBT community.”  That's up from 61% just three years ago. Additionally, 89% of secular Israelis support equal rights for homosexuals and transgenders compared to 75% of traditional Israelis, 53% of religious Israelis, and 25% of ultra-Orthodox Israelis. Judges 3:12 says, “Once again, Israel did what was evil in the sight of the Lord.” Brazil's attendance at sexually perverted “pride” event cut by 50% In related news, one of the world's largest sexual perverted so-called “pride” events has been held in São Paulo, Brazil. However, a university drone count found that the peak attendance fell off from 73,600 in 2024, to 36,800 in 2026. Organizers say the total attendees topped one million, but that's down from three to five million in recent years. Isaiah 2:10-11 promises this: “Enter into the rock, and hide thee in the dust, for fear of the Lord, and for the glory of His majesty. The lofty looks of man shall be humbled, and the haughtiness of men shall be bowed down, and the Lord alone shall be exalted in that day.” Trump scored elusive peace deal with Iran The United States and Iran have reached a deal aimed at ending the war that will reopen the Strait of Hormuz and lift the American naval blockade, reports NBC News. A signing ceremony is set for Friday in Switzerland. Global markets soared after the tentative deal was announced, while oil prices fell more than $4 a barrel on the news that shipping may soon be restored through the key trade route, according to Just The News. On Truth Social, Trump wrote, "Ships of the World, start your engines. Let the oil flow!” However, the memorandum of understanding leaves some key issues unresolved, setting up potential future tensions. The deal gives the two sides 60 days to resolve what to do about Iran's stockpile of highly enriched uranium and its nuclear program. Supreme Court sides with pro-abortion public school This just in.  The U.S. Supreme Court came down on the side of the pro-abortion lobby, to disallow a pro-life club from posting signs in a public school which would have denounced the abortion giant Planned Parenthood. Only Justices Samuel Alito and Clarence Thomas dissented. Justice Alito pointed out that the “Free Speech Clause of the First Amendment constrains censorship.” Many U.S. Christian denominations have lost members American denominations have lost church attendance since 2007. Pew Research breaks it down by denomination. Only the Reformed Churches and non-denominational groups have recovered or gained members since 2007. By percentage,  Holiness churches have lost the most members, followed by Methodists, Adventists, Restorationists, and Baptists. In raw numbers, Baptists have lost 11 million members, Methodists have lost seven million members, Lutherans have lost four million members, and Holiness groups have lost 1.6 million members since 2007. Meanwhile, the non-denominational churches gained 10.5 million members, and reformed churches gained about 150,000 over this 14-year period. Overall, the decline of faith in America has leveled off since 2019, largely due to an increased interest in church attendance on the part of Gen Z men between the ages of 14 and 29. Foreign Intelligence Surveillance Act was not reauthorized On June 11th, Congress did not reauthorize  the Foreign Intelligence Surveillance Act, or FISA. The vote was 198-218. FISA 702 has been used to spy on American citizens, and it actively circumvents the Fourth Amendment which prohibits the government from spying on Americans without a warrant. Almost all Democrats voted against reauthorization of FISA 702, but it took 19 Republicans to officially defeat the spying measure. Establishment Republicans signaled their disappointment that the measure was defeated, but Republican Congressman Tim Burchett of Tennessee explained, “The Fourth Amendment is there for a reason.” Trump saved 146,000 migrant children trafficked under Biden The Trump administration has rescued 146,000 migrant children who were trafficked into the country during the Biden administration. Department of Homeland Security Secretary Markwayne Mullin explained the situation and the conditions under President Biden. Listen. MULLIN: “We're going to right the wrongs that the Biden administration turned a blind eye to. It's because of President Trump's leadership. It's horrific what's happening right in our own country because of four years of a blind eye that allowed unvetted sponsors to come pick up 450,000 kids on our borders, knowing their reports. While the Biden administration was in office, their own reports reporting that over a third of the females, regardless of age, were sexually assaulted before they made it to the border.” Cleveland Clinic to invest $2 million to help de-transitioners In another domestic victory, the Trump administration reached a massive deal with the Cleveland Clinic Foundation which agreed to stop transitioning minors. The clinic also agreed to commit $2 million to help de-transitioners, following in the footsteps of Texas Children's Hospital, which set up a $10 million fund for that purpose.  Associate Attorney General Stanley Woodward stated, “The Department of Justice is steadfastly committed to protecting America's children. Just as the resolution with Texas Children's, today's resolution with Cleveland Clinic furthers that commitment and puts these providers on notice that this Department will vigorously enforce federal law where children are put at risk.” In Mark 9:42, Jesus said, “But whoever causes one of these little ones, who believe in Me, to stumble, it would be better for him if a millstone were hung around his neck, and he were thrown into the sea.” Artificial Intelligence can now clone your voice in a scam Please be aware!  Artificial Intelligence can now clone your voice with only three seconds of audio taken off of your voicemail greeting.  Artificial Intelligence scams increased twelve-fold in 2025.  Recent surveys have found one in four adults have encountered an Artificial Intelligence voice scam.  New York Knicks are world champions after a 53-year drought And finally, on June 13th, the New York Knicks became basketball world champions once again. ANNOUNCER: “It's over.  Knick fans: This is not a dream. Your long, long wait has ended. Go ahead and cry. After 53 years, the Knicks are finally NBA champions once again.” During Game 5 of the NBA Finals in the Alamo City, the New York Knicks defeated the San Antonio Spurs by a score of 94-90, capping off a stunning playoff run.  Knicks star Jalen Brunson scored 45 points in the victory, which earned him the nomination of Finals Most Valuable Player. But even more special for Jalen was the fact that his Dad, Rick Brunson, was his coach.  Amazingly, Rick, himself a former NBA player, made the finals for the New York Knicks back in 1999, also playing against the San Antonio Spurs in that series.  Rick and Jalen continue to maintain a close relationship, which Jalen elaborated on in a Good Morning America interview on ABC. BRUNSON: “Our relationship is unique. People may think just because he pushes me a certain way that we don't say things to each other, but I wouldn't trade anything for the world. We have the best relationship, even when it looks like we're fighting. That's just a coach and player trying to get over, to get to the Promised Land.” Close And that's The Worldview on this Tuesday, June 16th, in the year of our Lord 2026. Subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus. (Adam@TheWorldview.com) Seize the day for Jesus Christ.

A massage therapist notices that more clients are reporting their use of topical hormone medications. Somehow, this never came up in massage school. Is the massage therapist at risk for being dosed? It's possible, but it's nuanced. Listen for more information! Resources: Commissioner, O. of the (2021) Investigation of skin-to-skin transfer risks of topically applied transdermal hormonal drugs, FDA. FDA. Available at: https://www.fda.gov/science-research/fda-stem-outreach-education-and-engagement/investigation-skin-skin-transfer-risks-topically-applied-transdermal-hormonal-drugs (Accessed: June 3, 2026). Could Testosterone Gel Exposure Pose Risk to Close Contacts? (2025) Medscape. Available at: https://www.medscape.com/viewarticle/could-accidental-exposure-testosterone-gel-risk-your-close-2025a1000qpg (Accessed: June 3, 2026). Estradiol Gel: Uses & Side Effects (no date) Cleveland Clinic. Available at: https://my.clevelandclinic.org/health/drugs/20075-estradiol-topical-gel (Accessed: June 4, 2026). Hariri, L. and Rehman, A. (2026) "Estradiol," StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK549797/ (Accessed: June 4, 2026). Khan, S. and Sharman, T. (2026) "Transdermal Medications," StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK556035/ (Accessed: June 3, 2026). Medication Patches and Implications for Massage Therapy | ABMP (no date). Available at: https://www.abmp.com/Massage-and-Bodywork-Magazine/Issues/julyaugust-2024/medication-patches-and-implications-massage-therapy (Accessed: June 3, 2026). Should I be worried about secondary transfer risk with testosterone gels? (no date). Available at: https://www.trted.org/articles/should-i-be-worried-about-secondary-transfer-of-my-testosterone-gel (Accessed: June 4, 2026). Sjöström, K. et al. (2022) "A review of adverse events in animals and children after secondary exposure to transdermal hormone‐containing medicinal products," Veterinary Record Open, 9(1), p. e48. Available at: https://doi.org/10.1002/vro2.48. Types of Estrogen Hormone Therapy (no date). Available at: https://www.webmd.com/menopause/which-type-of-estrogen-hormone-therapy-is-right-for-you (Accessed: June 4, 2026). Host Bio:               Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.     Sponsors: Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.     Website: anatomytrains.com     Email: info@anatomytrains.com           Facebook: facebook.com/AnatomyTrains                      Instagram: www.instagram.com/anatomytrainsofficial YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA    Precision Neuromuscular Therapy seminars (www.pnmt.org) have been teaching high-quality seminars for more than 20 years. Doug Nelson and the PNMT teaching staff help you to practice with the confidence and creativity that comes from deep understanding, rather than the adherence to one treatment approach or technique. Find our seminar schedule at pnmt.org/seminar-schedule with over 60 weekends of seminars across the country. Or meet us online in the PNMT Portal, our online gateway with access to over 500 videos, 37 NCBTMB CEs, our Discovery Series webinars, one-on-one mentoring, and much, much more! All for the low yearly cost of $167.50. Learn more at pnmt.thinkific.com/courses/pnmtportal!  Follow us on social media: @precisionnmt on Instagram or at Precision Neuromuscular Therapy Seminars on Facebook.   Save your hands for the smaller structures and start getting your clients underfoot! At the Center for Barefoot Massage, we teach you how to enhance your pressure using gravity and physics and help your clients recover from persistent pain through nerd-level anatomical attention to detail—we just happen to use our feet to do it all! From the slow, down-regulating glides of our FasciAshi Fundamentals strokes to the proprioceptive "pattern-interrupts" of our Barefoot Matwork techniques and the resisted movements from our Stretch Therapy class, we offer a complete suite of evidence-based tools for deep, myofascial Ashiatsu Barefoot Massage—we nicknamed our approach "FasciAshi." Worried about your body size in relation to your clients? Our innovation—the suspended Ashi-strap—allows a more diverse population of massage therapists to regulate and vector their weight and pressure distribution with clinical precision, making deep work effortless on a variety of client bodies. At the Center for Barefoot Massage, we believe the future of massage is afoot! Find when and where our CE classes are happening next at centerforbarefootmassage.com.    

Dr. Brick Lantz of the Christian Medical and Dental Association addresses the recent decision by the Cleveland Clinic ending youth transgender procudures, as well Health and Human Services' move to protect the lives of frozen human embryos.  He also talks about a new sunscreen just approved by the FDA.  Vibrant Faith's Rick Lawrence continues talking about Jesus's kindness with us, even when we are dissappointed with Him and what He allows in our lives.   The Reconnect with Carmen and all Faith Radio are made possible by your support. Give now: Click here

What happens when you combine the clinical expertise of a registered dietitian with the comprehensive training of a board-certified family medicine physician? You get a powerful, preventative approach to healthcare that looks at the whole person.In this episode of Real Fuel with SLS, Stevie Lyn Smith catches up with longtime college friend and colleague, Dr. Alex Ford, DO, RD. Dr. Ford shares his unique journey from studying dietetics at Buffalo State to navigating the rigorous world of medical school, serving as Chief Resident at the prestigious Cleveland Clinic, and earning a spot on Albany's 40 Under 40 list. They dive deep into the gaps in traditional medical education regarding nutrition, the rise of GLP-1 medications, and how to champion true, preventive lifestyle medicine.In this episode they chat more about:The anatomy of whole-person careGLP-1s as tools as part of lifestyle medicineThe foundational pillars for every human looking to improve healthDr. Ford's career path and educationMaking nutrition information digestible and easy for individuals to apply to their livesThe reality of nutrition education in medical school (or lack thereof)And so much more!Stay Connected:Stay up to date with Dr. Ford: https://www.dralexford.com/Connect with Dr. Ford at  info@neotritionbrands.com, for general questionsFollow Stevie on Instagram: @stevielynlynJoin Stevie's newsletter: Stevie Lyn Nutrition newsletterLearn more about Dr. Alex Ford: If you enjoyed this episode, please leave a 5-star rating and review on Apple Podcasts or Spotify—it helps more athletes and health-conscious individuals find the show!

Artificial intelligence in legal cases The use of artificial intelligence is a topic of concern in legal cases, both by attorneys and parties to lawsuits they file. On Monday's "Sound of Ideas," we examine precedent being set in both situations in our latest installment of our "Law of The Land" series, where we look at how the law impacts our everyday lives. We start the conversation talking about how attorneys are using AI, both properly and improperly, in ways that affect not only client confidentiality and the cost for representation, but the way the judicial system functions, as a whole. Then, we look at ongoing lawsuits like the $1.5 billion case connected to Anthropic, an AI company which admitted using pirated copies of books to train its large language models known as "Claude." We explore the precedent these cases might set for compensation for artists of all kinds. Guests:-D. Allan Asbury, Deputy Director and Senior Counsel, Ohio Supreme Court Board of Professional Conduct-Rohit Nath, Attorney, Susman Godfrey L.L.P. Cleveland Clinic's settlement with the Department of Justice bars gender-affirming care for minors The Cleveland Clinic has become the second medical institution to reach an agreement with President Donald Trump's Department of Justice related to fraudulent billing allegations, specifically associated with gender affirming care for people under the age of 18. In the back half of Monday's edition of the "Sound of Ideas," we continue our "Law of The Land" series by sorting through the settlement which includes a payment of $300,000 from the Clinic to be split between the state of Ohio and the DOJ, and a commitment to set aside $2 million to cover the cost of detransitioning care for those seeking it who cannot afford it. The Clinic has also agreed not to provide puberty blocker and hormone treatments to minors for the next 20 years, which extends beyond current requirements under Ohio's House Bill 68, a law which has been in effect since 2024. In May, Texas Children's Hospital agreed to pay $10 million dollars and establish the nation's first "detransition clinic." In the Cleveland Clinic settlement, the Department of Justice called gender affirming care for minors "misguided medical interventions." Critics are calling this agreement a lapse in medical integrity, amounting to cruelty and anti-trans hate. Particularly, the emphasis on funding detransition care is being called unnecessary, bigoted and performative. When we reached out to the Clinic ahead of this segment, a spokesperson told Ideastream Public Media via email that the Clinic remains focused on providing exceptional care to its patients and communities. In our conversation, we talk through the DOJ's allegations against the Clinic and what the settlement entails. We'll also share a statement from the Cleveland Clinic on the agreement, and learn why an Ohio advocacy group is disappointed in this result, to say the least. Guests:-Dara Adkison, Executive Director, TransOhio-Justin Glanville, Deputy Editor of Engaged Journalism, Ideastream Public Media

Cancer is never convenient, and it never arrives when a patient is truly prepared, according to Daniel C. McFarland, DO, who began the most recent episode of Oncology On the Go with this sentiment. When individuals enter the high-stakes, highly coordinated world of oncology, they do so under extreme duress, often presenting the versions of themselves that are most under stress. In this environment, clinical teams frequently encounter behaviors that get unfairly lumped into the vague and pejorative category of the “difficult patient.” What happens when these challenges stem from an underlying personality disorder rather than just temporary situational anxiety? In this episode, McFarland was joined by psycho-oncology expert Kaleena Chilcote, MD, to unpack the inner workings of personality styles and disorders within oncologic science. Together, they explored the Diagnostic and Statistical Manual of Mental Health Disorders (DSM) diagnostic framework, spanning the eccentric, dramatic, and anxious categories. They discussed how these enduring, pervasive traits impact a patient's health care journey. Shifting the conversation away from the stigma of labels, McFarland and Chilcote delivered actionable, real-world advice for oncology teams. They discussed how to utilize objective, descriptive charting; initiate a pause to check your own provider emotions; and build highly consistent, structured boundaries. From managing frequent phone calls to intentionally scheduling short, high-frequency touchpoints, the pair provided a roadmap for turning interpersonal conflict into therapeutic collaboration, proving that underneath the defense mechanisms, every patient has a uniquely valuable strength to connect with. McFarland is the director of the Psycho-Oncology Program at Wilmot Cancer Center and a medical oncologist who specializes in head, neck, and lung cancer, in addition to being a psycho-oncology editorial advisory board member for the journal ONCOLOGY®. Chilcote is director of Psycho-Oncology in the Department of Palliative and Supportive Care at the Taussig Cancer Center, part of the Cleveland Clinic. 

This week we go back 2.5 years and delve into the world of cardiovascular surgery when we review a review of STS data on the pulmonary artery band (PAB). The STS assigns a STAT category of 4 to this operation, denoting higher risk for mortality. Is this warranted? Are all PAB candidates equal? What features are associated with higher or lower mortality rates in patients undergoing banding? Should the data in this work drive innovation to avoid the PAB in some settings? These are amongst the questions posed to the senior author of this week's work, cardiovascular surgeon Dr. Tara Karamlou who is Professor of Surgery at the Cleveland Clinic in Cleveland, Ohio. DOI: 10.1016/j.athoracsur.2023.09.020

Zac Wolfe is known for his grit and determination. He is a great example of how you can live a full life with a spinal cord injury and still maintain the fire to push for better outcomes. A few years ago, Zac enrolled in a Department of Defense, SCIRP-funded clinical trial using Transcranial Direct Current Stimulation (TDCS) to improve upper limb function. In this conversation we bring on Zac and the principal investigator of the study, Dr. Ela Plow of the Cleveland Clinic, to discuss how TDCS works along with the details of the study and what function Zac recovered. We also talk about the role of belief and determination in study participants, the importance of advocacy, why siloed thinking hinders research progress, how small functional gains become cascades for additional recovery and much more. This is an interesting conversation that I know you'll enjoy, so let's get to it! More info: https://u2fp.org/get-educated/curecast/episode-144.html

A marathon legislative session this week in Columbus produced several measures that we'll be unpacking here to begin the show. We start with what didn't get done: new rules for data centers. That legislation went off the rails over tax abatement. Data centers currently receive a 100% sales tax exemption. Proposed legislation would have reduced that tax break to between 50% and 75%. But many lawmakers, responding to concerns from constituents, say the industry should receive no exemption at all. Property tax relief remains a priority for Ohioans and lawmakers took action during their marathon session to provide help qualifying senior and disabled homeowners. More than 700,000 Homestead Exemption recipients will receive a nearly $500 credit toward their tax bill in January. Voters will decide whether to put photo-identification requirements for in-person voters – already a law in Ohio – into the constitution after lawmakers approved a constitutional amendment for the fall ballot. In a separate measure lawmakers sent to the governor a bill that extends voter ID to those casting votes by absentee/mail-in ballot. Ohio Republicans who say they are concerned about fraud in Medicaid in Ohio passed new regulations but first stripped out a provision that would have denied funding for those who care for sick family members. That provision had sparked spirited protests at the Statehouse. The Cleveland Clinic agreed to a deal with the Department of Justice this week that will end gender-affirming care for minors for at least the next 20 years. Prompted by an investigation into billing irregularities for such care, the agreement would remain in effect even if the current state law prohibiting gender-affirming care would be overturned. The MetroHealth System will not seek recertification of its Level 2 pediatric trauma center in 2027, though it will still treat children through its broader Level 1 trauma center for adults which also can treat minors. It will transfer pediatric cases to University Hospitals, which runs the region's only Level 1 pediatric trauma center, saying it's better for the broader system not to duplicate efforts. We will discuss these topics and the rest of the week's news on the “Sound of Ideas Reporters Roundtable.” Guests:- Abbey Marshall, Local Government Reporter, Ideastream Public Media- Conor Morris, Education Reporter, Ideastream Public Media- Karen Kasler, Bureau Chief, Ideastream Statehouse News Bureau

Surveillance and Bill Pulte's leadership, rescuing exploited children, helping children avoid online temptations, and fighting Ebola. Plus, Daniel Suhr on Cleveland Clinic's decision, stuck in concrete, and the Thursday morning newsSupport The World and Everything in It today at wng.org/donateAdditional support comes from St. Dunstan's, inviting young men into the building arts and the adventure of holiness on a Blue Ridge Mountains farm... stdunstansacademy.orgFrom Ascend by Unbound. A real-world, faith-centered college alternative for gap-year, trades, and degree-seeking students. More at beunbound.us/worldAnd from WatersEdge. Where faithful investments strengthen ministry. 4.6% APY on a 15-month term. WatersEdge.com/invest WatersEdge securities are subject to certain risk factors as described in our Offering Circular and are not FDIC or SIPC insured. This is not an offer to sell or solicit securities. WatersEdge offers and sells securities only where authorized; this offering is made solely by our Offering Circular.

In this episode, Donna and Tom sit down with Jennifer Becka, Global Sourcing Leader at Intuit and a supply chain innovator with over 15 years of global sourcing experience across manufacturing, healthcare, and technology. Jennifer shares insights from her diverse career journey, from managing the world's largest powered industrial fleet at Amazon to leading procurement transformation at GE, Cleveland Clinic, and Diebold, and now driving AI-powered sourcing at Intuit. Jennifer explores the critical distinction between resilient and anti-fragile supply chains, explaining how organizations can build systems that don't just withstand stress but actually improve because of it. She discusses the evolution of value creation from physical goods to digital services, strategies for earning executive buy-in through stakeholder collaboration, and her groundbreaking end-of-life fleet initiative at Amazon that optimized total cost of ownership. Takeaways: The difference between resilient and anti-fragile supply chains How value definition evolves across physical goods, healthcare services, and digital platforms Strategies for stakeholder engagement and earning executive buy-in Lifecycle management and total cost of ownership optimization Jennifer's career philosophy: building systems strong enough to improve under stress Stay connected with CSCR on LinkedIn (Center for Supply Chain Research) and Instagram (@pennstatesupplychain), and be sure to follow us on Spotify, Apple Podcasts, or wherever you are tuning into Unpacked: Insights hosted by the Penn State Smeal Center for Supply Chain Research™. Thank you for joining us!  Visit our website: https://www.smeal.psu.edu/cscr  Guest Bio: Jennifer F. Becka leads Accelerating Functions and Services Sourcing at Intuit. With over 15 years of global sourcing leadership, Jennifer has built and transformed procurement functions across manufacturing, healthcare, and technology—including leadership roles at GE, Diebold, Cleveland Clinic, and Amazon, where she directed global categories spanning the world's largest powered industrial fleet and critical digital security and marketing services. Known for building high-performing teams and driving enterprise transformation, Jennifer brings a rare combination of operational rigor, strategic vision, and technical fluency—including a Lean Six Sigma Black Belt, and certifications with ASCM and AI for Business Strategy. Jennifer is a member of the Penn State Smeal Executive DBA Cohort of 2029, where her research explores the governance of agentic AI in cognitive supply chains. She is based in San Diego, California.

Southern Baptists vote on women pastors...U.S. Catholic bishops gather tomorrw in Florida...and Cleveland Clinic to fund destransitioning care.

Lisa Salberg sits down with Dr. Nicholas Smedira of the Cleveland Clinic to explore how HCM surgery has evolved over the past three decades. They discuss myectomy, myosin inhibitors, surgical innovation, patient selection, and why experience and high-volume centers continue to matter in achieving the best outcomes for patients.   This conversation was recorded June 8, 2026.

Ashleigh Lindemann spent 17 years in pain before anyone could tell her why. Starting at age 15 with what turned out to be endometriosis, she navigated misdiagnoses, eight prescription medications out of Cleveland Clinic, and 17 surgeries, including the hip surgery that finally uncovered the answer hiding in plain sight. Refusing to accept a lifetime on Cymbalta and Neurontin, Ashleigh took the slow, determined road toward natural healing — and eventually found PEMF therapy (Pulsed Electromagnetic Field therapy), a technology she describes as earthing and grounding "on steroids." Now the owner of Pulse for Life LLC in Post Falls, Idaho, Ashleigh uses PEMF, red light therapy, and hyperbaric oxygen to help clients reduce inflammation, accelerate healing, and give their cells the energy God designed them to run on.HealingStrong's mission is to educate, equip and empower our group leaders and group participants through their journey with cancer or other chronic illnesses, and know there is HOPE. We bring this hope through educational materials, webinars, guest speakers, conferences, community small group support and more.Please take advantage of our FREE resources below to help you along your health and healing journey:Support Group DirectoryHolistic Curriculum - Participant GuideSupport Our Mission - DonateAdditional Health ResourcesListen to Previous EpisodesWebsite: healingstrong.org

GLP-1 medications like Ozempic and Wegovy are changing bodies fast. But what happens to your skin, face and overall appearance after dramatic weight loss? In this episode, Lauren sits down with New York Plastic & Reconstructive Surgeon Dr. David Kashan to talk about the growing rise in “Ozempic face,” loose skin, body contouring, facelifts, skin removal surgery and the very real aesthetic side effects many people aren't talking about. Dr. Kashan, who trained at the renowned Cleveland Clinic, shares what he's seeing firsthand in his practice during the GLP-1 boom. Together, they discuss who is most affected by rapid weight loss, the most common procedures patients are requesting now, how long patients should stop GLP-1 medications before surgery, and whether non-surgical treatments can help improve skin laxity, facial volume loss and overall skin quality before considering surgery. If you're a woman in midlife navigating weight loss, aging, confidence, skin changes or considering GLP-1 medications yourself, this conversation is packed with honest insight, practical advice, and expert perspective you'll definitely want to hear. Show Notes David L. Kashan MD, FACS, Plastic & Reconstructive Surgery (516) 515-9267 Website: davidkashanmd.com Instagram: @davidkashanmd  

Dr. Margarita Fedorova discusses the effectiveness of shunting for idiopathic normal pressure hydrocephalus.  Show citation:  Luciano MG, Williams MA, Hamilton MG, et al. A Randomized Trial of Shunting for Idiopathic Normal-Pressure Hydrocephalus. N Engl J Med. 2025;393(22):2198-2209. doi:10.1056/NEJMoa2503109   Show transcript:  Dr. Margarita Fedorova: Welcome to Neurology Minute. My name is Margarita Fedorova and I'm a neurology resident at the Cleveland Clinic. Today we're reviewing a randomized trial that provides high quality evidence for treatment we've been using for decades, shunting for idiopathic normal pressure hydrocephalus. The PENS trial, a placebo controlled effectiveness and iNPH shunting trial was published in the New England Journal of Medicine in December 2025 by Luciano and colleagues. This international multicenter study enrolled 99 patients across the United States candidate in Sweden. While idiopathic normal pressure hydrocephalus or iNPH is characterized by triad of gait impairment, cognitive decline in urinary continence, these findings can be non-specific and we mass factor in radiological findings too. Furthermore, while CSF shunting has long been the standard treatment, its effectiveness has never been rigorously confirmed in a large well-powered randomized trial. In this trial, patients with a clinical improvement in gait velocity after temporary CSF drainage were deemed eligible for shunting and randomizing the trial. What makes this trial particularly elegant is its blending strategy. All 99 participants underwent the same surgical procedure with the same commercially available programmable shunt valve. After surgery, the valve was set either to an open functioning position or to a high resistance placebo setting. Neither patients nor assessors knew who had a working shunt. This is about as close to a true double-blind design as neurosurgery can get. The primary outcome was changing gait velocity at three months. The open shunt group improved by 0.23 meters per second on average, while the placebo group showed essentially no change in 0.03 meters per second. That's a treatment difference of 0.21 meters per second, both statistically significant and clinically meaningful. To put that in perspective, a change of 0.10 meters per second is considered the threshold for substantial meaningful change in the elderly. 80% of the open shunt group exceeded that threshold compared to only 24% of the placebo group.  The Tenet scale, which measures gait imbalance, also showed significant improvement in the open shunt group. However, screening measures for good condition using the MoCA scale and bladder symptoms did not reach significance at three months, though tertiary outcomes for cognitive testing, quality of life and functional independence tended in favor of shunting. Importantly, falls were more common in the placebo group at 46% compared to 25% in the open shunt group. This is a meaningful safety signal given how dangerous falls are in older adults. There were also real risks with active shunting. Subdural hematomas occurred in 12% of the open shunt group versus 2% of placebo and three even required surgical intervention. Positional headaches from low CSF pressure were more common in the open shunt group at 59% versus 28%. The good news is that the adjustable valve allowed non-invasive management of many of these complications. While this trial gives us reasons to be cautiously optimistic about shunting for appropriately selected iNPH patients, it's worth noting that we only have evidence for improvement in gait and follow-up is only three months.  Longer-term data is still being collected so we don't know yet how durable these benefits are. If you want to read more, please find the paper by Mark G. Luciano, et al. It's titled A Randomized Trial of Shunting for Idiopathic Normal Pressure Hydrocephalus published in the New England Journal of Medicine in December 2025. That's your neurology menu for today. Keep exploring and we'll see you next time. 

In this episode, Tracy Peffley, System Vice President of Revenue Cycle Management at Cleveland Clinic, joins the podcast to discuss strengthening financial performance while improving the patient financial journey. She shares insights on the organization's physician advisory program and explores how AI is expected to shape the future of revenue cycle operations and patient engagement.

Dr. Casandra MacLeod discusses central retinal artery occlusions, recent trials, and those anticipated in the future.  Show citation:  Préterre C, Gaultier A, Obadia M, et al. Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. Lancet Neurol. 2025;24(11):909-919. doi:10.1016/S1474-4422(25)00308-4  Poli S, Grohmann C, Wenzel DA, et al. Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial. Int J Stroke. 2024;19(7):823-829. doi:10.1177/17474930241248516  Ryan SJ, Jørstad ØK, Skjelland M, et al. A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion. N Engl J Med. 2026;394(5):442-450. doi:10.1056/NEJMoa2508515 Show transcript:  Dr. Casandra MacLeod Hello, this is Casandra MacLeod, a neurology resident at Cleveland Clinic with today's Neurology Minute. Today we will be discussing central retinal artery occlusions, or CRAOs, and the recent trials that have come out and even those further on the horizon. The 2026 American Heart Association and American Stroke Association guidelines for the early management of patients with acute ischemic stroke were recently published and in them highlight the uncertainty around the treatment of acute CRAOs with intravenous thrombolysis, even when the patient presents within four and a half hours and is otherwise eligible. These guidelines come after two recent trials, which we will further discuss. The thrombolysis in patients with acute central retinal artery occlusion, or the THEIA trial, was published in the November issue of Lancet Neurology. This multicenter trial out of France randomized 70 patients with acute CRAOs presented within four and a half hours of time from last known well to either receive IV alteplase and oral placebo or IV placebo and oral aspirin. While safety measures showed no symptomatic hemorrhage event, although they did have one asymptomatic intracerebral hemorrhage occur, the primary outcomes, which included visual acuity improvement at one month, showed some evidence for a trend of improved acuity in the IV thrombolytic group at 66% compared to 48 in the aspirin group, it did not reach significant. And now more recently, the Tenecteplase in central retinal artery occlusion study, or TenCRAOs, was published in the January 2026 issue of The New England Journal of Medicine. TenCRAOs was a six European country multicenter trial that randomized 78 patients with CRAOs all presenting within four and a half hours of time from last known well to either receive IV Tenecteplase or aspirin, both with placebo-matching as in THEIA. The primary outcomes of TenCRAOs also included visual acuity at one month, but unfortunately this trial also did not show [inaudible 00:02:07]. They showed 20% in the IV TNK group compared to 24% in aspirin. And additionally, there was one fatal intracerebral hemorrhage in the TNK group that should be considered. Overall, the AHA and ASA guidelines state the usefulness of treatment with intravenous thrombolysis is uncertain. And this is based largely on these studies as neither trial showed improved visual recovery. Although both of these trials are underpowered, leading many to believe that the jury is still out on the use of IV thrombolytics in CRAOs. But importantly, stay on the lookout for one last trial. The early reperfusion therapy with intravenous alteplase for recovery of vision and acute central retinal artery occlusion, or the Revision trial, is actively recruiting. Revision is similar in design as THEIA, but with a goal of up to 422 total patients for a goal of a well-powered study to guide decision making. 

This brief episode is about mysophobia or germophobia. When I went to do my research, a lot of search engines wanted me to learn about misophonia.  The AI didn't believe that I wanted to learn about the fear of germs. It insisted that I wanted to know about the sensory brain problem where certain noise patterns are painful to hear or be exposed to for a person.    It is a very interesting condition but it is not an anxiety condition.  For those about to roast me for not spelling germophobia correctly, per the dictionary, both germophobia and germaphobia are correct. It is getting rough on these internet streets. It was like, hey little girl, let me tell you something you didn't ask for but I'm going to give it to you anyway.    This is why you need a brick in your purse. But I digress. This is a short look at this particular type of phobia. Resources Mentioned:  WonderMind is a website that writes about mental health and fitness issues for adults of a certain age, not boomers. They have a post called  How to Do Life When You're Scared of Germs. The Cleveland Clinic has an explainer page about mysophobia aka germophobia.   The International OCD Foundation has an abundance of resources about OCD information.    Emergency Resources: The Trevor Project: Provides crisis support specifically for LGBTQ+ youth through phone (1-866-488-7386), text (START to 678-678), and online chat. Available 24/7. They also provide peer support and community.    Veterans Crisis Line: Call 988 and press 1, text 838255, or chat online. There are phone lines for those serving overseas. Visit the website to find the current status of the Veteran line and international calling options.    National Crisis Text Line: Text HOME to 741741 for free, confidential support 24/7. This service operates independently of the 988 service. Users can use text, chat or WhatsApp as a means of contact.   Disclaimer:  Links to other sites are provided for information purposes only and do not constitute endorsements.  Always seek the advice of a qualified health provider with questions you may have regarding a medical or mental health disorder. This blog and podcast is intended for informational and educational purposes only. Nothing in this program is intended to be a substitute for professional psychological, psychiatric or medical advice, diagnosis, or treatment.

It's Friday, May 29th, A.D. 2026. This is The Worldview in 5 Minutes heard on 140 radio stations and at www.TheWorldview.com.  I'm Adam McManus. (Adam@TheWorldview.com) By Adam McManus and Jonathan Clark 180 Christian families denied communal water in India More than 180 Christian families in 32 villages across Chhattisgarh State in central India have reportedly been denied access to communal water sources and livelihood opportunities for the past three weeks as punishment for refusing to leave their Christian faith, reports International Christian Concern. Many Christian families in the Antagarh region of the district have been barred from using community rivers, ponds, taps, and hand pumps. At the same time, Christians have been denied work under a government employment scheme.  2 Timothy 3:12 says, "Indeed, all who desire to live a godly life in Christ Jesus will be persecuted." According to Open Doors, India is the 12th most oppressive country worldwide for Christians. Trump's accelerating squeeze on Cuba The Trump administration is bracing for the potential collapse of Cuba's totalitarian government as early as this summer, and has war-gamed new military response plans in case the island descends into chaos, reports Axios. President Trump will keep pushing economic sanctions to try to strangle the regime in Havana in a slow-motion constriction. This methodical squeezing of Cuba's communist regime is also designed to buy time for Trump — who's now engrossed in peace talks with Iran — to eventually focus on Cuba and decide how to bring about change there. The Cuba operation aims to eliminate Latin America's source of Marxist agitation and anti-U.S. activism ever since Fidel and Raul Castro led their successful revolution in 1959. To bring Cuba to its knees this year, the administration first focused on the island's lifeline: Venezuela, which is 1,200-miles south, and its socialist dictator, Nicolás Maduro. Venezuela kept Cuba afloat with shipments of oil that helped power the country and gave it a source of export revenue. Former Attorney General Pam Bondi has thyroid cancer Former U.S. Attorney General Pam Bondi was diagnosed with thyroid cancer shortly after her departure from office earlier this year and is now receiving treatment, reports USA Today. Bondi, age 60, was fired by President Donald Trump in April but is set to return to the Trump administration to serve on an advisory committee on artificial intelligence policy as she battles cancer. Thyroid cancer results from malignant cells growing in a person's thyroid gland, the butterfly-shaped gland at the base of your neck that makes hormones, according to the Cleveland Clinic and Mayo Clinic. These hormones regulate how your body uses energy, including metabolism, heart rate and blood pressure. Jill Biden wondered whether Joe had a stroke mid debate Remember this pivotal moment in the 2024 presidential debate between Joe Biden and Donald Trump? BIDEN: “Making sure that we continue to strengthen our health care system. Making sure that we're able to make every single solitary person eligible for what I've been able to do with the uh, with the COVID, excuse me, with, um, with dealing with everything we have to do with.  Look, if.  We finally beat Medicare!” As First Lady Jill Biden watched her husband stumble through the most cringeworthy portion of his disastrous June 2024 debate, she wondered if he had unknowingly ingested drugs or was having a medical episode on live television. In an upcoming CBS News Sunday Morning interview she said this. JILL BIDEN: “As I watched it, I thought, ‘He's having a stroke!' And it scared me to death.” However, at the time, right after the debate two years ago, Jill Biden said this. JILL BIDEN: “Joe, you did such a great job! You answered every question. You knew all the facts.” In her new biography entitled, View From the East Wing, she was far more candid. She wondered, “Is he short-circuiting? Is this a stroke? I felt like we were watching an AI hologram of the man we knew, and the hologram was glitching. Has he been drugged?” According to The Atlantic, which has seen a preview copy ahead of the June release, Jill Biden wondered, “Will people watching assume this is how he is all the time?” Bidens fighting to squelch embarrassing audio recordings Gary Bauer, founder of American Values and the co-host of Family Talk, wrote, “Right now, the Bidens are fighting to prevent closed-door audio recordings of interviews Joe Biden did from being released to the public. Why? Because in those interviews Biden couldn't remember basic events in his life. He couldn't remember when he was vice president. He couldn't remember when his son, Beau, died. He couldn't remember the advice his generals gave him.”   Bauer concluded, “And we all remember what Special Counsel Robert Hur said. Hur did not charge Biden for keeping classified documents because no jury would convict an ‘elderly man with a poor memory.' In other words, Joe was not mentally competent to stand trial.” Teenage worker bees drops to lowest level since 1948 The number of teenagers working jobs this summer is expected to fall to the lowest level since 1948. The consulting firm Challenger, Gray & Christmas predicts teens will gain 790,000 jobs in May, June, and July. That's down from 801,000 last summer. The firm noted, “Rising inflation, climbing oil prices, and a broadly cautious hiring environment are expected to keep the 2026 summer hiring total well below historical averages as employers and consumers rein in spending.” Welsh preacher John Penry pleaded for Welsh evangelism before execution And finally, on May 29,1593, 433 years ago today, Welsh Protestant preacher John Penry appealed for Christian pastors to proclaim the Gospel of Jesus Christ in Wales shortly before his execution under the reign of Queen Elizabeth I. John Penry wept for Wales. He noted that thousands of Welsh had never heard of Christ. He wrote, “O destitute and forlorn condition! Preaching itself in many parts is unknown. In some places, a sermon is read once in three months.” Penry proposed a system of lay pastors supported in part with voluntary gifts from the people. His attack on the neglectful behavior of the Church of England won Penry the undying hostility of John Whitgift, the Archbishop of Canterbury, reports the Christian History Institute. Having become a Puritan Separatist in his thinking, Penry could not accept a state-run system because, "The truth of Christ” could not be in bondage to an “anti-Christian power.” Because of such outspoken views, and his stern warnings to Queen Elizabeth I and her bishops, Penry had to flee. Because he dared to expose the Church of England for its neglect, John Penry was captured and treated to a travesty of justice. Some strong words of warning against the queen in his notebook were interpreted as treason. Archbishop Whitgift was the first to sign his death warrant. Penry was hauled off to be hanged on this day, May 29, 1593. A thin scattering of bystanders, none of them his friends, watched as the 34-year old departed this world at the end of a rope about four in the afternoon. He was not allowed to preach a final sermon. He had, however, written a lengthy letter to his four daughters named Deliverance, Comfort, Safety, and Sure Hope -- who ranged in age between 4 and four months. He implored them to follow the true faith. James 1:12 says, “Blessed is the one who perseveres under trial because, having stood the test, that person will receive the crown of life that the Lord has promised to those who love Him." Close And that's The Worldview on this Friday, May 29th, in the year of our Lord 2026. Subscribe for free by Spotify, Amazon Music, or by iTunes or email to our unique Christian newscast at www.TheWorldview.com.  Plus, you can get the Generations app through Google Play or The App Store. I'm Adam McManus (Adam@TheWorldview.com). Seize the day for Jesus Christ.

President Trump uses a wide-ranging White House cabinet meeting to tout his administration's record, press Iran to make a deal, address energy concerns, and respond to the latest security scare near the White House. Former Attorney General Pam Bondi reveals she is being treated for thyroid cancer as Axios reports she is returning to the Trump administration as a liaison on the president's science and technology advisory council. A new Cleveland Clinic study finds GLP-1 drugs like Ozempic and Mounjaro are associated with slower progression in several major cancers, though researchers caution the findings do not prove the drugs caused the improved outcomes. NASA announces a new round of lunar missions and private-sector contracts aimed at testing the landers, vehicles, cargo systems, and survival infrastructure needed to return astronauts to the Moon and eventually reach Mars.   SelectQuote: Compare top‑rated life insurance options. Visit https://SelectQuote.com/megyn to get the right coverage at the right price.   Cozy Earth: This Memorial Day, visit https://www.CozyEarth.com & Use code MEGYN for up to 30% off Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of Head and Neck Innovations, Edward Doyle, MD, and Varun Kshettry, MD, join host Paul Bryson, MD, to discuss the diagnosis and management of cerebrospinal fluid (CSF) leaks and encephaloceles. They explore common presentations, advances in imaging and diagnostic testing, and collaborative surgical approaches for skull base repair. The conversation also highlights the growing recognition of idiopathic intracranial hypertension as an underlying cause of spontaneous CSF leaks, as well as emerging treatment strategies including venous sinus stenting, weight management, and GLP-1 receptor agonists.

Acompañe a Raisa Santana, MA, CCC-SLP —patóloga de habla y lenguaje clínica bilingüe (español/inglés) de la Cleveland Clinic— en una charla dirigida a los padres sobre cómo apoyar las necesidades de comunicación únicas de su hijo.

Carlos Rodrigues spent 20 years in Canadian financial services. Mutual funds, life insurance both levels, and a full mortgage broker with five agents under him. He tried to start his own fund. Canadian compliance costs killed it. Now he drives 4.5 hours each way from Hamilton to Cleveland, Ohio to buy duplexes for $70,000 that appraise at $170,000 after renovation. In this episode, we get into: The $70,000 duplex near the Cleveland Clinic with a toilet falling through the floor How Section 8 rentals pay 20 to 30% above market, with one tenant paying $14 of her $1,400 rent Why 100% loan-to-cost financing is back, and why this isn't 2008 The joint venture partner who added $30,000 to $40,000 in renovation scope while Carlos was at Home Depot The contractor who ghosted him a week before closing How ICE enforcement is hitting the US construction labor pool Cleveland's side yard program: buy a vacant lot next to your house for $100 Why Carlos won't invest in Hamilton anymore, even though he lives there Plus my own update: my Hamilton duplex tenant has been non-paying for 7 months, $12,000 deep, and we're still waiting on the LTB. This is the world we're operating in. Want the investment loan strategy that produced a 40.6% return since September 2025? I'm hosting a free training on Saturday May 30 (Oakville hybrid) and Tuesday June 2 (Zoom only). Walking through the complete strategy, the math, every loss scenario, and how it fits alongside a real estate portfolio. Register at: ⁠https://wealthhacker.krtra.com/t/uqyHFbipnPrK⁠Connect with Carlos: Website: cashflowcarlos.com, Instagram & TikTok: @cashflowcarlos Connect with Erwin: Podcast: tafipod.ca Free Wealth Freedom Blueprint: infinitywealth.ca/freereport Book a Wealth Planning Call: linked at ⁠www.infinitywealth.ca⁠ 

Most of us know overwork isn't good for us. But the research on just how damaging it can be, and how quietly the damage accumulates, is more sobering than most people realize.In this episode of The Mind–Gut Conversation, Dr. Emeran Mayer reflects on his own experience of sustained overwork throughout his career. We're talking 80-hour weeks, chronic sleep disruption, borderline hypertension, and eventually atrial fibrillation. He also digs into what the science says about why this pattern is so common and so easy to miss.Drawing on findings from the World Health Organization, the Cleveland Clinic, and Harvard Business Review, he explores the biological and behavioral mechanisms through which chronic overwork damages the body over time, identifies six key warning signs that your work-life balance is already off, and makes a practical case for reconnecting with physical signals that most of us have learned to override.Topics discussed include:Why working more than 54 hours a week is linked to measurable increases in stroke and heart disease riskWhat allostatic load is and how chronic stress accumulates invisiblySix red flags that signal your work-life balance is offDr. Mayer's personal experience with atrial fibrillation and what prompted a rethinkThe role of mindfulness, movement, and nature in nervous system recoveryWhy your body keeps the score, even when you're not paying attentionThis is a candid, evidence-based episode for anyone who has normalized pushing through exhaustion and wonders what it may be costing them.Connect with Dr. Mayer:Website: https://www.emeranmayer.comInstagram: https://www.instagram.com/emeranmayer/X: https://x.com/emeranmayermdFacebook: https://www.facebook.com/EmeranMayerMD/LinkedIn: https://www.linkedin.com/in/emeranmayer/Chapters:0:00 – Introduction0:35 – The Science of Overwork1:06 – Dr. Mayer's Personal Experience3:00 – Six Warning Signs4:55 – Reconnecting with Your Body

Most of us know overwork isn't good for us. But the research on just how damaging it can be, and how quietly the damage accumulates, is more sobering than most people realize.In this episode of The Mind–Gut Conversation, Dr. Emeran Mayer reflects on his own experience of sustained overwork throughout his career. We're talking 80-hour weeks, chronic sleep disruption, borderline hypertension, and eventually atrial fibrillation. He also digs into what the science says about why this pattern is so common and so easy to miss.Drawing on findings from the World Health Organization, the Cleveland Clinic, and Harvard Business Review, he explores the biological and behavioral mechanisms through which chronic overwork damages the body over time, identifies six key warning signs that your work-life balance is already off, and makes a practical case for reconnecting with physical signals that most of us have learned to override.Topics discussed include:Why working more than 54 hours a week is linked to measurable increases in stroke and heart disease riskWhat allostatic load is and how chronic stress accumulates invisiblySix red flags that signal your work-life balance is offDr. Mayer's personal experience with atrial fibrillation and what prompted a rethinkThe role of mindfulness, movement, and nature in nervous system recoveryWhy your body keeps the score, even when you're not paying attentionThis is a candid, evidence-based episode for anyone who has normalized pushing through exhaustion and wonders what it may be costing them.Connect with Dr. Mayer:Website: https://www.emeranmayer.comInstagram: https://www.instagram.com/emeranmayer/X: https://x.com/emeranmayermdFacebook: https://www.facebook.com/EmeranMayerMD/LinkedIn: https://www.linkedin.com/in/emeranmayer/Chapters:0:00 – Introduction0:35 – The Science of Overwork1:06 – Dr. Mayer's Personal Experience3:00 – Six Warning Signs4:55 – Reconnecting with Your Body

Dr. Margarita Fedorova discusses whether a vaccine ingredient is quietly protecting the brain.  Show citation:  Taquet M, Todd JA, Harrison PJ. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. NPJ Vaccines. 2025;10(1):130. Published 2025 Jun 25. doi:10.1038/s41541-025-01172-3 Show transcript:  Dr. Margarita Fedorova:  Welcome to Neurology Minute. My name is Margarita Fedorova, and I'm a neurology resident at the Cleveland Clinic. Today we're exploring a study that raises a compelling question. Could a vaccine ingredient be quietly protecting the brain? A recent study by Taquet et al., published in npj Vaccines in 2025, investigated whether vaccination with an AS01-adjuvanted vaccine is associated with a lower risk of dementia. You might know it as the immune-boosting ingredient in Shingrix, the shingles vaccine, and Arexvy, the new RSV vaccine. We already know from prior work that the Shingrix vaccine was associated with a reduced risk of dementia, but the question this paper asks is why. Is it because preventing shingles itself protects the brain, or is there something specific about the adjuvant that's doing the work? To answer this, the researchers used a large US electronic health record database comparing over 35,000 people who received the AS01-adjuvanted RSV vaccine, over 100,000 who received the AS01-adjuvanted shingles vaccine and over 78,000 who received both. Each matched against individuals who got the seasonal flu vaccine instead. The findings were interesting. People who received the RSV vaccine had a 29% lower risk of new dementia diagnosis over the following 18 months. Those who received the shingles vaccine had an 18% increase in time without dementia, and those who received both had a 37% increase in dementia-free time. Here's a key insight. Both vaccines target completely different viruses, but both contain the same adjuvant. The fact that a similar protective signal was seen with both suggests the benefit may not be about which virus is prevented, and it may be about the AS01 itself. Why might an adjuvant protect the brain? AS01 contains two active components, monophosphoryl lipid A, known as MPL, and QS21. Together they activate macrophages and dendritic cells, triggering cascade that includes a production of interferon gamma. In animal models, stimulation of a receptor called toll-like receptor 4, which MPL activates, has been shown to reduce Alzheimer's-like pathology. The authors also point out that the protective effect appears within just a few months of vaccination, which is hard to explain purely by prevented infections and may point instead to a direct immunological mechanism. Very important caveat. This is an observational study, not a randomized trial, so we can't prove causation. There was also uncertainty about which brand of RSV vaccines some patients received, which could affect the strength of the AS01-specific conclusion. And with all of the dementia studies, it's unclear whether the vaccines prevent dementia or delay its onset. Though even a delay would be clinically meaningful given how few tools we have. What does this mean for clinical practice? For now, it doesn't change your vaccination recommendations. Both Shingrix and Arexvy already indicated in appropriate patients for the primary purposes, but it adds an intriguing possible benefit when counseling patients who ask about vaccines. And it opens the door to a genuinely exciting question. If AS01 has neuroprotective properties, could it be studied in a therapeutic target in its own right? That's the Neurology Minute for today. Keep exploring and we'll see you next time. If you want to read more, please find the paper by Maxime Taquet, et al., titled Lower Risk of Dementia with AS01-Adjuvanted Vaccination Against Shingles and Respiratory Syncytial Virus Infections, published in npj Vaccines in June 2025. 

You're scheduled for surgery and your surgeon says "you don't need to do anything to prepare." That's medical gaslighting.  In this episode of The Medical Disruptor, I sit down with Dr. Becky Knackstedt, a plastic and reconstructive microsurgeon at Duke with an MD, PhD, and functional medicine certification from the Cleveland Clinic. She's published over 80 peer-reviewed papers and she's done what almost no surgeon does. She questioned what she was taught. We get into why surgical prehabilitation dramatically cuts complications, infections, and hospital stays, and why the system still isn't doing it.  Dr. Becky breaks down the protein, vitamin D, and probiotic protocols that actually move the needle on recovery, why just 5 days of targeted nutrition can change your outcome, and the microbiome connection that nobody in surgery is talking about. She also blows up some of the most damaging pre-op myths still being repeated in operating rooms across the country. Omega-3s, estrogen patches, and IUDs do not need to be stopped before surgery, despite what you've been told.  This is the conversation every patient needs before they sign the consent form. Whether it's breast reconstruction, orthopedic surgery, or a cosmetic procedure, the weeks before matter just as much as the surgery itself.  You are not powerless and you are not just a body on a table. You have a role in your own recovery and this episode shows you exactly how to use it. Want more practical health tips? Join my newsletter! https://freechapter.lpages.co/newsletter-opt-in/ Check us out on social media: https://www.instagram.com/drefratlamandre https://www.facebook.com/drefratlamandre https://www.tiktok.com/@drefratlamandre #functionalmedicine #drefratlamandre #medicaldisruptor  #NPwithaPHD #nursepractitioner #medicalgaslighting Chapters 0:00 Meet Dr. Rebecca Knackstedt 0:30 Her background & credentials 1:00 Why surgery training wasn't enough 2:29 The broken surgical prep model 3:21 Why surgery ignores lifestyle 4:21 Insurance is the real barrier 5:20 What is prehabilitation? 6:56 The full prehab approach 8:10 5 days of immunonutrition 9:26 Bromelain, protein & wound healing 10:22 Clearance vs. true optimization 11:21 The patient who changed everything 13:42 What she started doing differently 15:56 Pain catastrophizing in surgery 16:51 Vitamin D — what you need to know 19:13 Daily vs. weekly Vitamin D dosing 20:49 The microbiome & surgery connection 22:12 Probiotics before surgery 23:46 What labs & assessments matter pre-op 25:57 Why surgeons are pushing back 28:00 How to advocate for yourself 29:33 Why she built Clara Recovery 31:27 Medical gaslighting in surgery 35:28 What to do weeks before surgery 38:35 Advice for clinicians Guest Links: FB: https://www.facebook.com/profile.php?id=61567434996173 IG: https://www.instagram.com/surgical_recovery/ YT: https://www.youtube.com/@UCw9aFvRFjNiyiQG3vPkS05Q  Website:www.clararecovery.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Chronic inflammation is silently driving some of the most common diseases today — and most people have no idea it's happening. In this episode, Nurse Doza breaks down five hidden triggers: poor sleep, refined grains, low vitamin D, omega-3 deficiency, and digestive issues — and exactly what you can start doing about each one today. FEATURED PRODUCT Liver Boost – MSW Nutrition Chronic inflammation doesn't just live in your joints or your gut — your liver is at the center of it all. The liver filters inflammatory byproducts, processes environmental toxins, manages hormones, and supports fat digestion. When it's overburdened, your inflammatory load goes up. Liver Boost from MSW Nutrition is formulated with N-acetyl-L-cysteine (NAC), milk thistle, and selenium to support liver detoxification, protect your antioxidant defenses, and ease the total burden your body is carrying — making it a natural complement to everything discussed in this episode.

Send us Fan MailThe hardest part of health care isn't always treatment, it's figuring out who should treat you in the first place. Speaking of Women's Health Podcast host Holly L. Thacker, MD sits down with Laura Lipold, MD, Director of Primary Care Women's Health at Cleveland Clinic, to map out how primary care, OB-GYN care and consultative women's health specialists can work together across every life stage.They talk candidly about why so many patients feel stuck right now, from limited access to primary care to the long shadow of menopause misinformation after the Women's Health Initiative. You'll hear practical guidance on what primary care can often handle (Pap tests, HPV and cervical cancer screening, mammogram orders, chronic disease management, obesity and metabolic health, behavioral health support) and when it's time to bring in a specialist for complex menopause and hormone therapy decisions, severe osteoporosis, cancer survivorship, blood clots, transplants, or major cardiovascular history.Support the show

Women make up about two-thirds of people diagnosed with Alzheimer's disease, but experts say longer life expectancy alone does not explain the gap. Dr. Jessica Caldwell's research focuses on how sex and gender influence Alzheimer's disease risk, resilience, and progression, including the roles of genetics, menopause, lifestyle factors, and life stressors. Caldwell is a neuropsychologist and investigator of the Wisconsin Registry for Alzheimer's Prevention, or WRAP, at the Wisconsin Alzheimer's Institute, as well as a visiting associate professor in the Department of Neurology at UW–Madison. She previously directed the Women's Alzheimer's Movement Prevention Center at Cleveland Clinic, the first Alzheimer's prevention center designed exclusively for women.In this conversation with Being Patient's Mark Niu, Caldwell explained how the disparity is influenced by multiple factors, including genetics, menopause, estrogen loss, medical conditions, lifestyle, and caregiving-related stress. She discussed why midlife may be an important window for prevention, especially for women. Caldwell also described how hormonal changes during menopause, symptoms such as hot flashes and depression, and chronic stress may affect brain health, while lifestyle factors such as exercise, nutrition, medical care and social connection may help support resilience.---If you loved listening to this Live Talk, visit our website to find more of our Alzheimer's coverage and subscribe to our newsletter: https://www.beingpatient.com/Follow Being Patient: Twitter: https://twitter.com/Being_Patient_Instagram: https://www.instagram.com/beingpatientvoices/Facebook: https://www.facebook.com/beingpatientalzheimersLinkedIn: https://www.linkedin.com/company/being-patientBeing Patient is an editorially independent journalism outlet for news and reporting about brain health, cognitive science, and neurodegenerative diseases. In our Live Talk series on Facebook, former Wall Street Journal Editor and founder of Being Patient, Deborah Kan, interviews brain health experts and people living with dementia. Check out our latest Live Talks: https://beingpatient.com/live-talks/

After years of misdiagnoses, medication sensitivities, injuries, and setbacks, a massage therapist is diagnosed with Functional Neurological Disorder (FND), a condition that causes non-typical seizures and intermittent paralysis-like weakness. Despite being unable to work, she continues advocating for the FND community and wants to help educate massage therapists about the benefits of safe, informed touch for people living with the condition. In this episode of IHACW. . ., Ruth explores Sarah's journey, the realities of FND, and the role massage therapy may play in supporting those navigating complex neurological challenges.  Resources: Functional Neurologic Disorder | National Institute of Neurological Disorders and Stroke (no date a). Available at: https://www.ninds.nih.gov/health-information/disorders/functional-neurologic-disorder (Accessed: May 8, 2026). Functional Neurologic Disorder | National Institute of Neurological Disorders and Stroke (no date b). Available at: https://www.ninds.nih.gov/health-information/disorders/functional-neurologic-disorder (Accessed: April 28, 2026). Functional Neurological Disorder (Conversion Disorder) (no date). Available at: https://my.clevelandclinic.org/health/diseases/17975-conversion-disorder (Accessed: April 28, 2026). Functional Neurological Disorder, Reframed | Harvard Medicine Magazine (no date). Available at: https://magazine.hms.harvard.edu/articles/functional-neurological-disorder-reframed (Accessed: May 8, 2026). Ranford, J. et al. (2020) "Sensory Processing Difficulties in Functional Neurological Disorder: A Possible Predisposing Vulnerability?," Psychosomatics, 61(4), pp. 343–352. Available at: https://doi.org/10.1016/j.psym.2020.02.003. "What Is FND" (no date) FND Hope International. Available at: https://fndhope.org/fnd-guide/ (Accessed: April 28, 2026). What Is Functional Neurological Disorder (FND)? (no date) Cleveland Clinic. Available at: https://my.clevelandclinic.org/health/diseases/17975-conversion-disorder (Accessed: May 8, 2026).  Host Bio:              Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.    Sponsors: Anatomy Trains is a global leader in online anatomy education and also provides in-classroom certification programs for structural integration in the US, Canada, Australia, Europe, Japan, and China, as well as fresh-tissue cadaver dissection labs and weekend courses. The work of Anatomy Trains originated with founder Tom Myers, who mapped the human body into 13 myofascial meridians in his original book, currently in its fourth edition and translated into 12 languages. The principles of Anatomy Trains are used by osteopaths, physical therapists, bodyworkers, massage therapists, personal trainers, yoga, Pilates, Gyrotonics, and other body-minded manual therapists and movement professionals. Anatomy Trains inspires these practitioners to work with holistic anatomy in treating system-wide patterns to provide improved client outcomes in terms of structure and function.      Website: anatomytrains.com     Email: info@anatomytrains.com           Facebook: facebook.com/AnatomyTrains  Instagram: www.instagram.com/anatomytrainsofficial YouTube: https://www.youtube.com/channel/UC2g6TOEFrX4b-CigknssKHA    Precision Neuromuscular Therapy seminars (www.pnmt.org) have been teaching high-quality seminars for more than 20 years. Doug Nelson and the PNMT teaching staff help you to practice with the confidence and creativity that comes from deep understanding, rather than the adherence to one treatment approach or technique. Find our seminar schedule at pnmt.org/seminar-schedule with over 60 weekends of seminars across the country. Or meet us online in the PNMT Portal, our online gateway with access to over 500 videos, 37 NCBTMB CEs, our Discovery Series webinars, one-on-one mentoring, and much, much more! All for the low yearly cost of $167.50. Learn more at pnmt.thinkific.com/courses/pnmtportal!  Follow us on social media: @precisionnmt on Instagram or at Precision Neuromuscular Therapy Seminars on Facebook.   At Heights Wellness Retreat, we believe every person is an unstoppable force, whether navigating daily demands, pursuing goals, or striving to be their best. This drives everything we do. We go beyond traditional spa services by creating a purpose-driven environment where wellness professionals are empowered, valued, and positioned to grow. With steady clientele, support, and a wellness-forward culture, Heights Wellness Retreat is where therapists build meaningful, sustainable careers while shaping the future of the wellness industry.  www.massageheightscareers.careerplug.com/jobs  www.heightswellnessretreats.com  https://www.instagram.com/heightswellnessretreat/  https://www.facebook.com/heightswellnessretreat/   

In this episode of Parallax, Dr Ankur Kalra welcomes Dr Eunice Dugan, a graduating interventional and structural heart disease fellow at the Cleveland Clinic, as she prepares to transition into independent practice in Fort Wayne in the summer of 2026. Dr Dugan reflects on how early mentorship shaped her decision to engage with the American College of Cardiology during fellowship, and what professional societies can offer beyond the clinical environment — from expanding skill sets and building lasting networks to driving meaningful change. She shares how her role as a local FIT representative led her to organise a widely attended webinar helping fellows navigate the new interventional cardiology match. The conversation also tackles the attrition challenge that affects many early-career cardiologists in their first three to five years of practice: Dr Dugan, now transitioning into the ACC's Early Career Council, discusses the "fog" of establishing a new career and makes the case for cultivating a specific project during fellowship as a professional anchor through the pressures of a new post, relocation, and family life. She also speaks to her advocacy for women in cardiology, including championing open discussion around family planning and reproductive strategies — topics that remain underaddressed in the field. Questions and comments can be sent to podcast@radcliffe-group.com and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

In this episode of The House of Surgery, Drs. Katrin Arnolds and Ana Pena discuss the realities of operating while pregnant. Drawing from their own experiences as surgeons and mothers, they share practical tips for staying safe and comfortable in the OR, managing prenatal appointments, navigating workplace expectations, and reducing exposure to radiation, anesthesia gases, surgical smoke, chemotherapy agents, and other potential hazards. This conversation offers valuable insight for pregnant surgeons, trainees, and anyone working alongside pregnant members of the surgical team. Talk about the podcast on social media using the hashtag #HouseofSurgery Katrin Arnolds, MD, is a board-certified minimally invasive gynecologic surgeon at the Cleveland Clinic in Weston, Florida Ana Pena, MD, FACS, is a board-certified general surgeon at the Cleveland Clinic in Weston, Florida     Copyright © 2026 by the American College of Surgeons (ACS). All rights reserved.   The contents of this podcast may be cited in academic publications but otherwise may not be reproduced, disseminated, or transmitted in any form by any means without the express written permission of ACS. These materials may not be resold nor used to create revenue-generating content by any entity other than the ACS without the express written permission of the ACS. The contents of these materials are strictly prohibited from being uploaded, shared, or incorporated in any third-party applications, platforms, software, or websites without prior written authorization from the ACS. This restriction explicitly includes, but is not limited to, the integration of ACS content into tools leveraging artificial intelligence (AI), machine learning, large language models, or generative AI technologies and infrastructures.

What if everything you've gone through in life — the chaos, the loss, the addiction, the grief — was the exact preparation you needed to save someone else's life?Dan Flanagan grew up surrounded by strong values of integrity, hard work, and loyalty, anchored in the rhythm of small-town Ohio life and Catholic faith. His childhood had a kind of Norman Rockwell quality to it — a baseball field in the backyard, dirt bikes, snowmobiles, his mom ringing a bell to call the kids in for dinner. But underneath that idyllic surface, something harder was brewing.Dan's dad, his hero, his best coach, was secretly battling severe clinical depression. When Dan was 15, his dad went away to a psychiatric unit an hour from home to undergo treatment and was gone for over a year. His mom held down the fort working 12-hour days.The sudden loss of his parental anchor left Dan and his siblings with too much freedom, few role models, and an onslaught of confusion and pain. He went off the rails. Started drinking, making bad choices, falling in with the wrong crowd.The darkness in his family didn't stop with his dad. His brother Sean also developed mental illness in college and attempted suicide more than once.Dan managed to earn a degree and build a sales career out of sheer determination and grit, the unresolved trauma and anger simmered beneath the surface. He masked his struggles with alcohol and bravado, insisting that everything was “fine,” when he was far from it.The turning point came on May 6th, 2019, when he finally said enough. He enrolled himself in an intensive outpatient program at the Cleveland Clinic, started showing up at the gym at 4:45 AM, and began listening obsessively to Eric Thomas, Tony Robbins, Jocko Willink, and David Goggins — anyone who had built something from nothing and come out the other side.About a year into his sobriety, he was listening to a Jocko podcast and heard about Dr. Daniel Amen, a world-renowned psychiatrist who developed brain SPECT imaging, a tool that shows what's happening in a living brain rather than just guessing. Dan ordered the book “The End of Mental Illness” before he even got home. And sitting on his couch that Saturday, something cracked open. He describes it as a spiritual moment, followed by a question that felt like it came from somewhere bigger than him: what if all of this was the preparation?Motivated to make a difference, Dan leveraged his story and his sister's expertise to launch the Brain Enrichment Initiative, a peer-to-peer mentoring and mental wellness program for students. Rooted in authenticity and vulnerability, the program aims to help young people break the silence around emotions, teaching them proactive brain health strategies and creating space for real connection.The urgency behind BEI is very real to Dan. He is out there doing the work every single day — for his family, for those kids, and for every version of himself that didn't have someone showing up to say: your brain can get better, and so can you.Hype Song: Dan's hype song is Zach William's “Survivor” https://www.youtube.com/watch?v=8R4tdF2s42w Resources: Dan Flanagan's website www.bei-neo.org LinkedIn: https://www.linkedin.com/in/dan-flanagan-a4934850/ Facebook: https://www.facebook.com/dqflanagan Instagram: https://www.instagram.com/dqflan/ Invitation from Lori:This episode is sponsored by Zen Rabbit.Smart business leaders know trust is the foundation of every great workplace. And in today's hybrid and fast-moving work culture, trust isn't built in quarterly town halls or the occasional Slack message. It's built through consistent, clear, and HUMAN communication.Companies and leaders TALK about the importance of connection and community. And it's easy to believe your organization is doing a great job of maintaining an awesome corporate culture. Because you've got annual all-hands and open door policies, and “fun" team-building events.But let's be real. Leaders who are serious about building real trust are finding better ways to strengthen culture, create connection, and foster community.That's where I come in. Forward thinking companies are hiring me to produce internal/private podcasts. To bring leadership and employees together through authentic stories, real conversations, and meaningful connections. Think of it as your old-school printed company newsletter - reinvented for the modern workforce. I KNOW, what a cool idea, right?!If you run, work for, or know of a company that wants to upgrade communication, facilitate connections, build community, and maintain culture, let's chat. Message me at Lori@ZenRabbit dot com.Because when people feel heard, they engage.

If just thinking of spiders is enough to make the hairs stand up on the back of your neck, or you jump any time you see one, the chances are you suffer from arachnophobia. It affects up to 15% of people according to the Cleveland Clinic, making it one of the most common phobias out there. As it turns out, human fear of spiders may well be down to evolution. Researchers from Germany, Austria and Sweden looked into the question in more detail for a study published in Frontiers in Psychology in 2017. This may be because such creatures have historically provided a threat. Some other studies have also backed up the idea of an inherited fear of spiders.  But my friend keeps pet spiders; why doesn't she have the same fear as me? So can it be cured? ⁠⁠In under 3 minutes, we answer your questions !⁠⁠ To listen to the latest episodes, click here: ⁠⁠Will the British museum finally give back the Parthenon marbles?⁠⁠ ⁠⁠What did the Jane Collective do for US women's rights?⁠⁠ ⁠⁠What is tagskryt, the Scandinavian sustainable travel trend?⁠⁠ A podcast written and realised by Joseph Chance. First Broadcast: 21/9/2022 Learn more about your ad choices. Visit megaphone.fm/adchoices

How Founders Can Partner With Medical Centers Frank McGillin returns to share key lessons for digital health founders to partner with academic medical centers, curated from his time leading The Clinic by Cleveland Clinic.  All that, plus the Flava of the Week about Rock Health's newly minted research on consumers' use of AI chatbots. How quickly are health-related AI searches growing, and what actions tend to come next?  Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In this episode, I'm breaking down the four pillars of recomposition to help you shrink your body fat, build lean muscle, and reclaim the energy you had in your 20s. For 30 years, the fitness world has preached the same rule: you have to "bulk" to gain muscle, or "cut" to lose fat. But modern science shows us a different path. It is entirely possible to do both at the same time through a process called Body Recomposition. Sponsors: Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Caraway Home: carawayhome.com/drjoshaxe (Use code DRJOSHAXE) for an exclusive discount Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: ⁠⁠⁠https://www.youtube.com/@drjoshaxe?sub_confirmation=1⁠⁠⁠ 

*Testosterone Directly Suppresses Brain Tumor Growth in Males by 38% Cleveland Clinic research funded by NIH shows testosterone binds androgen receptors in glioblastoma stem cells — the root of tumor recurrence — and cuts growth by 38% when levels are restored. Dave breaks down why the mainstream framing of testosterone and cancer risk has it backwards, what androgen deprivation therapy may be doing to every other cancer pathway simultaneously, and why your hormone panel is now a cancer conversation, not just a performance one. Sources: -https://www.nih.gov/news-events/news-releases/nih-funded-study-suggests-testosterone-suppresses-brain-tumor-growth-males -https://bioengineer.org/nih-funded-research-indicates-testosterone-may-inhibit-brain-tumor-growth-in-males/ *CDC Halts Rabies Testing Nationwide A CDC staffing crisis has pushed rabies, mpox, and Epstein-Barr testing to overwhelmed state labs, creating one-to-two week diagnostic delays in a disease where post-exposure prophylaxis must begin within ten days of a bite — and where fatality is virtually 100% once symptoms appear. Dave explains exactly what to do if you or a pet is exposed, why outdoor biohackers are the most exposed population, and what pre-travel prevention looks like for anyone heading to endemic regions. Sources: -https://www.nbcnews.com/health/health-news/cdc-pauses-testing-rabies-monkeypox-epstein-barr-viruses-rcna266377 -https://www.cidrap.umn.edu/rabies/state-public-health-labs-step-cdc-pauses-testing-various-pathogens-including-rabies-mpox *Mifepristone Mail Ban The Supreme Court issued a one-week stay blocking a 5th Circuit ruling that would have ended telehealth and mail access to mifepristone, used in over 63% of U.S. abortions. Dave sets aside the moral debate to focus on what this legal precedent means for FDA-approved compounded peptides, bioidentical hormones, and telehealth access to any treatment without full pharmaceutical backing — and why this case is one every biohacker should be tracking closely. Sources: -https://www.usnews.com/news/health-news/articles/2026-05-05/supreme-court-issues-stay-keeping-abortion-pill-mifepristone-available-by-mail-for-now -https://www.npr.org/2026/05/04/nx-s1-5810510/supreme-court-mifepristone-appeals-telehealth *Cow Flu and Dog Coronavirus University of Florida scientists are watching Influenza D — endemic in U.S. cattle herds — and canine coronavirus HuPn-2018, which already jumped to humans in China, as the two zoonotic threats most likely to achieve widespread human transmission. Dave covers why the conditions producing these jumps aren't going away, what the Influenza D finding means for the raw milk conversation right now, and the mucosal immunity stack that puts you in the strongest position regardless of which virus makes the leap next. Sources: -https://ufhealth.org/news/2026/scientists-say-these-two-viruses-may-become-the-next-public-health-threats -https://www.gavi.org/vaccineswork/six-major-health-threats-could-shape-2026-heres-what-experts-are-watching *Hantavirus Kills 3 on Cruise Ship Eight confirmed or suspected cases of Andes hantavirus aboard the MV Hondius off the Canary Islands have killed three and left two critical, with passengers from 23 countries already dispersed through global airports. Dave cuts through the pandemic panic to explain why American and South American hantavirus strains are categorically more lethal than European ones, why Andes is the only strain on earth that spreads human to human via respiratory droplets, and what early symptom recognition could mean for your survival window if exposure reaches your community. Sources: -https://www.cnn.com/2026/05/07/world/hantavirus-ship-tenerife-outbreak-intl -https://www.nbcnews.com/health/health-news/hantavirus-andes-virus-what-is-cruise-ship-outbreak-deadly-strain-rcna343901 This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on hormonal optimization, infectious disease risk, immune resilience, and the legal infrastructure shaping medical autonomy. Host Dave Asprey connects emerging NIH research, Supreme Court developments, and live outbreak data into actionable frameworks for protecting your biology when institutions can't do it for you. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: testosterone brain cancer, testosterone glioblastoma, low testosterone tumor risk, androgen deprivation therapy cancer, CDC rabies testing paused, rabies post-exposure prophylaxis, rabies exposure protocol, mifepristone telehealth ban, SCOTUS mifepristone stay, telehealth medical autonomy, compounded hormones legal risk, influenza D cattle virus, canine coronavirus HuPn-2018, zoonotic virus 2026, raw milk bird flu risk, mucosal immunity biohacking, hantavirus cruise ship, Andes hantavirus outbreak, MV Hondius hantavirus, hantavirus human to human transmission, hantavirus vs coronavirus, biohacking news 2026, Dave Asprey weekly roundup, longevity research 2026 Thank you to our sponsors! - Dave Asprey's 2026 Clean Nicotine Roadmap | Enroll for free at: daveasprey.com/2026-clean-nicotine-roadmap - Essentia | Go to https://myessentia.com/dave and use code DAVE for $100 off The Dave Asprey Upgrade. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:35 – 1. Testosterone & Brain Cancer 02:30 – 2. CDC Pauses Rabies Testing 04:09 – 3. Mifepristone & Telehealth Access 05:42 – 4. Influenza D & Canine Coronavirus 07:15 – 5. Hantavirus Cruise Ship Outbreak 09:36 – Takeaways See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Thursday Headline Brief of The Wright Report, Bryan delivers hopeful news for your pocketbook as U.S. oil producers begin ramping up drilling in Texas, New Mexico, and Venezuela, signaling that relief at the gas pump may eventually be coming—even as the world remains trapped in an oil squeeze caused by the war with Iran and the closed Strait of Hormuz. He breaks down President Trump's latest peace proposal to Tehran, which would require Iran to surrender its highly enriched uranium, halt enrichment for 15 years, and abandon underground nuclear facilities in exchange for lifted sanctions and a gradual reopening of Hormuz. Bryan explains why the next 48 hours could determine whether Iran's regime accepts a deal or risks economic collapse as oil storage runs out and the Trump blockade continues to choke off revenue. He also covers major domestic fallout from the attempted assassination of President Trump, including new confirmation that radical leftist attacker Cole Allen was partly motivated by the Iran war and anti-Trump rhetoric, plus controversy over a Democrat judge accused of showing sympathy toward the suspect. Bryan then highlights DOJ investigations into a Soros-backed Virginia prosecutor accused of protecting criminal illegal immigrants, a Virginia state senator facing bribery allegations tied to a cannabis business, and Barack Obama's latest comments on justice and the rule of law, which Bryan sharply challenges. Plus, Bryan reports on anti-ICE riots at a New York hospital, Texas' push to let police arrest and deport illegal border crossers, the White House effort to kill offshore wind projects in favor of oil and gas investment, and practical medical updates on testosterone and brain cancer, cranberry juice helping antibiotics fight UTIs, and a simple 10-minute floor routine that improves balance and mobility as we age.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Trump Iran peace deal proposal 2026 Strait of Hormuz reopening, US oil drilling Permian Basin Venezuela production gas prices summer 2026, Cole Allen Trump assassination attempt motive Iran war anti-Christ rhetoric, Virginia Soros DA Steve Descano DOJ investigation illegal immigrant crimes, Louise Lucas FBI raid cannabis bribery corruption Virginia, Obama Stephen Colbert interview rule of law criticism 2026, anti ICE riot NYC hospital Nigerian illegal immigrant arrest, Texas Senate Bill 4 immigration arrests deportation law, offshore wind farm cancellations Trump oil gas policy, glioblastoma testosterone treatment Cleveland Clinic study, cranberry juice UTI antibiotics research, 10 minute floor exercises balance mobility aging Japan study, Bryan Dean Wright podcast, The Wright Report  

There are many treatment options for people with relapsing MS. Patients should be carefully monitored to assess treatment response, and a change in treatment approach should be considered if safety concerns emerge. In this episode, Teshamae Monteith, MD, FAAN, speaks with Ellen M. Mowry, MD, MCR, and Daniel Ontaneda, MD, PhD, coauthors of the article "Treatment of Multiple Sclerosis" in the Continuum® April 2026 Multiple Sclerosis and Related Disorders issue. Dr. Monteith is the associate editor of Continuum® Audio and an associate professor of clinical neurology at the University of Miami Miller School of Medicine in Miami, Florida. Dr. Mowry is the director of the Multiple Sclerosis Experimental Therapeutics Program and a professor of neurology at The Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Ontaneda is the director of research at the Mellen Center for Multiple Sclerosis and a professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. Additional Resources Read the article: Treatment of Multiple Sclerosis Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @headacheMD Guest: @EllenMowryMD Full episode transcript available here Dr. Monteith: There are so many new treatment strategies for multiple sclerosis, which is a blessing, but it does come with the complexity of really just trying to nail down the approach. I just got finished talking to Drs Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis. We discussed relapses, weighing escalation versus early high-effective treatment and progressive disease. This is a must-listen-to podcast. I hope you enjoy it as much as I enjoyed talking to them.  Dr. Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr. Monteith: This is Dr. Teshamae Monteith. Today, I'm interviewing Ds Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Welcome, both of you. How are you?  Dr. Mowry: Great. And thank you so much for having us.  Dr. Monteith: Absolutely. So, why don't you both introduce yourself?  Dr. Ontaneda: All right. My name is Daniel Ontaneda. I'm a neurologist at the Cleveland Clinic. I spend the majority of my time doing research, but I still dedicate about a day a week to seeing people with MS in clinic.  Dr. Mowry: I'm Ellen Mowry. I'm also a neurologist, but practice at the Johns Hopkins University. And similar to Dan, I mostly work on research, but also have an active clinical care component, taking care of people with MS.  Dr. Monteith: Well, thank both of you for writing this article and being on our podcast. I assume you guys have probably known each other for quite a while now.  Dr. Mowry: Yes. Dr. Ontaneda: Yes. Dr. Monteith: What inspired you to get into multiple sclerosis research and then clinical care?  Dr. Ontaneda: I always loved neurology, and I think a lot of us who go into neurology are attracted to the complexity of the human brain and how the nervous system works. But what really hit home to me was a family member of mine who had multiple sclerosis, and he was being treated in a time where we really didn't have super effective disease-modifying medications. And so, as I went through my medical career, I always kind of kept an eye on what was happening with multiple sclerosis, and I started my training at a time where it was really flourishing in terms of the medications available, so that's what inspired me to go into MS. It's a disease that we can definitely treat, and you can change outcomes for people. So, that was it.  Dr. Monteith: Yeah, that personal experience can be very impactful.  Dr. Mowry: My journey started, actually, because I was thinking about whether I wanted to be a physician at all, and I happened to land, just after high school, a position with a neurologist who happened to mostly focus on multiple sclerosis and taking care of folks with multiple sclerosis. And by the end of the summer, I knew I wanted to go to med school and I wanted to be a neurologist and I wanted to work with people with MS. I thought I would be a clinician exclusively, but I think as time went on and I started to hear the consistent questions that people I served were asking in the clinic and realizing that those questions could be turned into research projects that could address their concerns, I moved more and more towards research. Dr. Monteith: Great. There are a lot of really detailed information in the article, so I think that research mind is very useful, and I see that in the writing. Why don't we talk about the goal of the article? Dr. Ontaneda: So, I think the goal of the article was to set out kind of what the large view of what treatment for multiple sclerosis looks like. And, you know, many times we divide the treatment of multiple sclerosis into these large pillars, and I think that's what we did in the article. The first was, you know, what do you do with a person who has an MS attack or relapse? The second is, what medications do we use to treat the relapsing forms of multiple sclerosis where there is a lot of acute inflammation, focal inflammatory lesions that are occurring? And then the final one is, what do you do with individuals who have a more progressive form of the disease where they're accruing disability slowly and gradually? Dr. Monteith: And what were some of the main points? Dr. Mowry: Dr. Okuda provided a really nice section on the treatment of acute relapses in multiple sclerosis, and it's important to understand what we talk about when we are saying "relapse". For people with MS, many symptoms can fluctuate and occur and then get better over time, and sometimes people with MS use the same term of "relapse" to describe those symptom fluctuations. As neurologists, when we're thinking about relapse, we're really trying to think about symptoms that can be attributed to new focal inflammatory events somewhere in the central nervous system. Typically, these are accompanied---if you were to get an MRI at the same time---by a new lesion or MS spot, as I like to call them, on MRI scan. And so, it's important to distinguish when somebody is talking about symptoms, whether they are true new symptoms that could be mapped to a place in the central nervous system. Because alternatively, a lot of people who've had attacks or relapses in the past can have what we call pseudo-relapses, and these are essentially recrudescence of old symptoms, typically in a similar pattern as what had occurred in the past. And these can be brought out by things like fever or infection, sometimes stress. And pseudo-relapses are not thought to be due to new development of immune system-induced injury and therefore would be less likely to respond to treatment; and in fact, treatment may be contraindicated for those events. We also talked a little bit in that article about how relapses are treated, talking about the use of high-dose steroids for true new relapses, but also kind of cautioning that those are not necessarily free of concerns, especially if you have a pseudo-relapse or there could be an infection going on. And that ultimately, the decision as to whether to treat a relapse really is a shared decision-making because it's thought that although the steroids can speed up recovery from a relapse, they may not have a major impact on ultimate recovery. And so, a lot of the shared decision-making comes in here because for a mild relapse, you might choose to forego a course of high-dose steroids.  Dr. Monteith: Daniel, any other main points?  Dr. Ontaneda: Yeah. On the side of treating relapses, I think one of the other things that probably has changed a lot, at least during the course of my training, is that in the past, whenever we had identified a relapse, as Dr. Mowry has clearly defined, we would typically treat with intravenous high-dose corticosteroids, typically with methylprednisolone. And that was kind of our go-to. We would either do it in an infusion center or we would set it up with home care. And I think one of the things that our field learned over, I would say, the last five or ten years is there's an abundance of studies that show that you can give that same dose of methylprednisolone. Rather than giving it IV, you can give it orally. No pun intended, as I tell my patients, a lot of pills to swallow because we use fifty-milligram prednisone pills, and they have to take 1,250 a day. The pharmacy always pushes back on that many pills, but really the advantage of being able to take steroids orally that way for three to five days is really, I think, one, better for people with MS because they can do it in the comfort of their own home, and two, I think also when you look at the costs associated with that treatment, it is the most cost-effective option. Dr. Monteith: And what are some of the latest developments that you're really excited about that weren't in the article?  Dr. Mowry: A lot of the article focused on the approach to treatment of people with what we've traditionally called relapsing/remitting multiple sclerosis. So, this is the kind of MS that traditionally presents with a relapse or an attack initially, although some of that nomenclature is changing, actually. And the article focused a lot on the strategies surrounding treatment of somebody with newly diagnosed relapsing MS, and thinking about this vast number of disease-modifying therapies that are available to people with MS and their clinicians, and how to think about the strategy with respect to largely centered around the efficacy class of the medication, whether people should take an approach of using a higher-efficacy therapy---meaning a medicine that in clinical trials was more likely on average to suppress relapses as well as new lesions---or whether there's still a good argument for the case of using an escalation approach, using some of the more modest efficacy medications that also probably in general have lower risks, monitoring for response to treatment and changing if the medication isn't working. And so, there's still a lot of debate in the field, I would say, even though many people have moved towards a one-size-fits-all kind of approach. I think there's still a lot of debate in the field about the evidence underlying that. And, you know, full disclosure, Dr. Ontaneda and I are each running parallel and very complementary clinical trial programs to address this very question, the results of which should be available within the next year, year and a half.  Dr. Monteith: Well, we can't wait that long. Give me some clinical pearls to how we initiate these modifying therapies. Like, what are the pearls that we need to have in our mind?  Dr. Ontaneda: Yeah. I think when we think about starting the disease-modifying therapy in an individual who has an active form of multiple sclerosis, I think, you know, one of the cornerstones I would say of making that decision is shared decision-making. I think we tend to sit down with the patient and analyze the data that we have at hand, what we know about their multiple sclerosis, and we use several factors to inform how likely we think their disease is gonna be active or potentially might not respond to the initial treatment you give. And we look heavily at the MRI. The MRI is really a useful marker because it shows us, one, how many lesions a person might have---both, you know, where those lesions are and also kind of the amount of lesions. Lesions, certainly, that are in the spinal cord, a very large burden of diseases. A lot of active lesions, which we determine by the presence of contrast-enhancing lesions, really helps us inform on disease severity. I would say that was our number one tool that we use to decide and help us decide how we think that person's MS is gonna do over time. And then the second thing that we put into the equation also is, you know, how well do we think this person is going to tolerate our medications? All our disease-modifying medications act through suppression of the immune system, and we know that that carries some risks associated with it. Some of those risks are stuff like infections. Some of those can be simple infections that really don't have major consequences, but some of them can be quite serious, including the need for hospitalizations or prolonged antibiotic treatment courses. And so, we also look at what, you know, the underlying risk of a person has for infection. This kind of is determined by, one, A, how many infections they've had up to date, and also how much disability they had. I would say in our average patient who when we see them, they're probably typically pretty young, in their twenties, thirties, forties, they typically don't have a lot of infectious risks. And therefore, I think there's kind of a move to saying, "Well, actually their risk of infections is quite low." And we put that together with, you know, also what the preference of the patient might want. So, do they prefer to take a pill, for example? Do they prefer a medication where they receive that via infusion every six months and they don't really have to think about it? There are some people that don't like going into a hospital, and they might prefer an injection type of those medications. And so, after a complex discussion of all those factors, we take into consideration how much risk the patient wants to take as well, and we come up with a rational choice of a couple of medication options. So, I think it's challenging sometimes because we have over two dozen medications. There's the risk of you saying, "There are these twenty-four medications, you can pick one." And I think our job as neurologists is to kind of pare those down, talk about, in a person like yourself, these are the two or three medications that I would recommend using. Why don't you review them? And then we bring them back, and we kind of make a final decision with, one of the key factors that I think is important to remind people is that you're gonna start this medication, and we are gonna monitor to make sure it's working. We're gonna monitor to make sure you're tolerating it well. And although it's an important, the first decision you make, I think one key theme that we tell people is, we can revise our strategy whenever we like. We just have to think about it and do it in a way that we think is gonna make sure that their MS is under the best control. And then we think about the ultimate goal of treatment, which, in multiple sclerosis, is the absence of any attacks and also the absence of any new lesions on MRI. And that's where whether you are offering more of the high-effective medications or more moderate- or low-efficacy medications, that's where there's a little bit of controversy still in our field, and that's what our trials are trying to answer.  Dr. Monteith: Excellent. So now we've selected a particular option- and I love those points with shared decision-making, using the MRI to guide and then kind of risk tolerance related to infection. But now a patient's still having relapses, and I know the goal is zero, but, you know, there's some margin. What are the pearls to advance to more high-efficacy therapies?  Dr. Mowry: Yeah, that's a great question. Dr. Ontaneda in the article actually talked about the literature surrounding monitoring for breakthrough disease and when to say this much is too much, and there's actually not a definite right answer. It's clear that more active disease early in the course is probably more of concern than, say, developing, you know, a new spot in your fifties or something to that effect. So, different people have different thresholds. I know at our center, we tend to be pretty on top of making changes for breakthrough disease. So, what we typically do is reimage people about six months after they start a medication to establish a new baseline. And sometimes, because of delays in starting or because the medications take a while to kick in, there might be a new spot or two. So, if that's the case, I really only get concerned if the spots are also taking up the dye or enhancing to indicate they're really quite recent, and I think, "Ugh, that's not something I'd like to see six months after starting a medication." And so that otherwise is sort of the reference scan, moving forward, to evaluate the medication, and I have a very low threshold for changing, particularly if somebody is on a moderate-efficacy therapy. To me, I think, well, our goal of trying the moderate efficacy therapy is essentially to see if we could get away with a medicine that is probably, on average, safer and that will still work for your MS. But if the answer is no, I personally don't like to stick around too much on them. One caveat I would say is that if somebody develops what appears to be a new lesion or spot on higher-efficacy therapy, before presuming that that new area of activity is a definite new MS event, I always like to rethink carefully, did I get the diagnosis correct? Or could this be an early infection such as, you know, progressive multifocal leukoencephalopathy in people on natalizumab in particular? Because I see breakthrough activity so rarely in people on higher-efficacy therapies that I just like to rethink my diagnosis and the differential prior to making switches to, typically, another higher-efficacy therapy in that case. But that, again, is a little bit of shared decision-making. It's sometimes contextual. If a person is using a self-administered medication and they have a little breakthrough, sometimes you can solicit some history, saying, "Oh, I actually kind of stopped taking it for a few weeks because something was going on, and I really want to retry." And that's very reasonable as well. Dan, do you have any other thoughts?  Dr. Ontaneda: No, I think I agree. That's really close to how I practice myself as well, and the majority of people at my center. I think that we are learning that when you start a treatment, many times---depending on how deeply you look---you can find evidence of ongoing disease, and that's something that we struggle with. It's almost like we have tools to treat inflammation in terms of new MS lesions and new relapses. And so, when those are present, it's pretty clear that you probably have to switch medication. I think a slightly trickier issue is when, for example, you have a person who might be stable. They don't have an attack. But you notice that they're worsening, and they tell you they're worsening. I think our ability and tools for that is a little bit harder, and we recognize that that can actually happen fairly early in the disease. And that's why we're trying to rethink this mantra that we've had for many years, where we kind of divide MS up into relapsing and progressive, and we see people develop progressive MS 10 to 15 years after they've had a relapsing form of the disease. So, I think that's just a reality of clinical practice. And we don't have as many tools to treat that gradual worsening, which is kind of what the rest of our article spent some time talking about. Dr. Monteith: You've also written about the clinical trial long-term extension studies. And what are the few points that you take away from the emergence of these types of publications over the past few years? Dr. Mowry: Yeah, well, long-term extension studies can be really helpful to understand whether the findings that are evidenced during the randomized portion of trials themselves continue into a longer term. And for people with MS, understanding these data can be really helpful because, particularly when we're looking for impact of a given treatment or a strategy on disability worsening, often it takes longer than the short-term portion of the trial to truly understand if the medication or strategy has an impact on insidious worsening that Dan is speaking about. Many trials have demonstrated a short-term benefit, but we think a lot of times that benefit is probably because of the reduction in relapses, which sometimes leave a permanent mark on neurologic function. But the extension studies are trying to understand a little bit more about whether the effect on disability worsening is sustained, and also to look a little bit more deeply at long-term safety, especially when it comes to medications that do increase the risk of infection. The caveats, though, in interpreting those types of studies are that people drop out, and so probably the people who drop out of those studies are really different. They may be either less disabled and they think, "Oh, you know, I'm done. I feel good." Or potentially more disabled and they think, "Ugh, I have more things to do I've got to take care of. What's going on?" And so that kind of dropout can produce some bias in interpreting the results. Dan, any other thoughts?  Dr. Ontaneda: No, I think that's spot on. I mean, I think that when we're trying to decide on what general philosophy to use, right? Like, you're seeing a patient for the first time. They've recently been diagnosed with MS, and you have... you know, I kind of bin them into three options. You can start a low-efficacy, a moderate, or a high-efficacy medication. And the first piece of information you could use is clinical trials, and Dr Mowry very clearly identified why some of that data might be a little bit biased and isn't, you know, completely applicable to the patient who's in front of you. The second thing that we might look at is observational data, and there's a wealth of observational data that shows that, in general, people on higher-efficacy medications tend to do better over time. But one of the challenges we have is that there's always biases related to those observational study designs. And so, I think you have to interpret them with a little bit of caution because there are reasons people start specific medications in people. And when you look at them in a purely observational study, even if you do some fancy way of addressing those biases, such as propensity, there always is the possibility of some residual bias. You know, that's part of the reason why we're doing the trials that Dr Mowry described, because we really need kind of long-term evidence to show that these medications actually can affect disability ten, twelve years after started. And I think pragmatic clinical trials, like the ones we're running, are really gonna be the key to answer those questions. We all have our favorite approaches right now, but I think that the data to actually demonstrate what's best for people with MS is really needed.  Dr. Monteith: Great, and there's so much in this article. I mean, we didn't even touch on radiological isolated syndrome, monitoring MS therapeutically, and treatment of progressive MS. Any final take-home points?  Dr. Ontaneda: Yeah. Maybe I will touch a little bit on the side of progressive MS, because it has been, you know, the MS that we historically have not been able to treat as much. So, we described there's over two dozen therapies approved for relapsing forms of MS. For purely progressive forms of MS that don't have any evidence of activity, we really only have one approved therapy, and it appears that that therapy actually does work through active inflammation anyway. And in the article, we highlighted examples of studies that have been negative, but also some recent examples of studies that have been positive, specifically with a new class of medication called BTKI, or Bruton tyrosine kinase inhibitors. We just recently heard of a second molecule that also had positive results in this realm. So, we're excited that, you know, in the next four to five years-  Dr. Monteith: I'm sorry. Can you just go ahead and say what that molecule...You're leaving people hanging.  Dr. Ontaneda: One molecule is tolebrutinib, which already has a positive study in secondary progressive MS in individuals without activity. And then the second compound that has been studied with positive trial results, we only have summary results from that, is a medication called fenobrutinib. And we think these two compounds that are part of a single class, the hope is that maybe they can address some of that gradual worsening that occurs in MS. And then the question comes whether we should use those from the get-go or if we should just use them later. So, a whole sort of variety of different questions. But I think important to call out for clinicians that this area where we had no available treatments for so many years might be changing.  Dr. Monteith: Well, thank you both. I really loved this conversation. I learned a lot listening to both of you, and I look forward to your clinical trial results.  Dr. Mowry: Thank you so much for having us. Dr. Ontaneda: Thanks so much. It was our pleasure. Dr. Monteith: Again, today I've been interviewing Doctors Ellen Mowry and Daniel Ontaneda about their article on treatment of multiple sclerosis, which they wrote with Dr. Darin Okuda. This article appears in the April 2026 Continuum issue on multiple sclerosis. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr. Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

In the second episode of this series, Dr. Justin Abbatemarco and Dr. Benjamin P. Trewin discuss what was found in non-steroidal maintenance therapies.  Read more about this abstract on the AAN website.   Show transcript:  Dr. Justin Abbatemarco: Hello and welcome back. This is Justin Abbatemarco from the Cleveland Clinic. And we're joined by Ben Trewin on his abstract maintenance immunotherapy and MOGAD, early steroid benefit, dose thresholds and disability risk. Ben, in our first episode we really talked about corticosteroids, but your paper and abstract looked at other therapies. What did you find in those non-steroidal maintenance therapies? Dr. Benjamin Trewin: In addition to looking at oral corticosteroid therapies, we also looked at B-cell depleting therapies, namely rituximab and ocrelizumab, and intravenous immunoglobulin and steroid-sparing therapies, namely azathioprine and mycophenolate predominantly, I suppose a couple on methotrexate. Now, what we found, it's important to note that we were able to tease apart the effects of all these drugs with our Cox proportional hazard model chops up, follow up into distinct intervals with different combinations and permutations of these medications and their different doses in a more granular way than is allowed by previous techniques like incident rate ratios when we compare pre and post annualized relapse rate, and we think this is a strength of the study. With this methodological strength, we were able to see that steroid-sparing therapies, despite 334 patient years of data, do not appear to have any independent benefit with respect to time to next relapse. The estimate of effect there was 1.06. And then for time to confirm sustained disability, there was also no confidence signal, the confidence interval being 0.15 to 1.4, that it actually prevented any disability despite a wealth of data, which I think is an important thing to note. And I think previous studies, particularly looking with incident rate ratios, have been a little more optimistic with that. And I think there might be misattributing some of the benefit of concomitant steroids to the steroid-sparers, but it's more complex than that, of course. And then with respect to B-cell depleting therapies, we did have 48 of 261 patients exposed, which is reasonable, but not quite enough to get the signal we're looking for. However, we found something quite interesting, because when we compared the Liverpool data to the Australasian data, the two big study groups involved, we saw that it wasn't quite as effective in Liverpool as it was in Australasia in this subgroup analysis. And so we dug a little deeper, as one should, and found that the dosing is actually different. And in Australasia, we have a tendency to just give two grams of rituximab up front, or 600 milligrams of ocrelizumab. And then six-monthly, you give a gram of rituximab without fail, without trying to watch the B cells or trying to muck around with doses in any way. And when we looked at that, the threshold dosing, as we termed it, as compared to below threshold dosing, there actually was weak evidence at a PVA of 0.08 that threshold dosing is superior to below threshold dosing. And that needs to be reproduced, but I think that was an important signal. And finally, I would say IVIG, of course, has some very strong data in this area. And I think it's important from this study at least to remain a little agnostic on that as we only had 31 patients on IVIG, and so I absolutely wouldn't say it's not effective. I would say unfortunately, we had insufficient data to make any big claims about that. Dr. Justin Abbatemarco: I think some really great data to help pick apart here and help inform practice. I think your point about looking at the previous literature and trying to tease apart these steroid-sparing agents, that corticosteroids they're not uniformly addressed, and so it's difficult to think about at those previous data points, so I appreciate that. And then this dose response to the B-cell therapies, there's been questions in the literature, because I think we've gotten a lot of mixed results on B-cell therapies. And so this to me is one of the larger studies that really help answer this question that maybe B-cell therapies are effective and maybe we need to be a little more sensitive to dose, which is the same theme we saw on IVIG. IVIG, maybe at higher doses, could be more effective for MOGAD. What do you think about that comparison? Dr. Benjamin Trewin: I like where you're going with that because we're quite interested in these dose responses as we introduce this 12.5 milligram per day oral corticosteroid dose or 0.16 milligrams per kilograms per day in kid. And so we're quite interested. And, of course, that work by Dr. Chen and Dr. Mariner has revealed that IVIG also has quite a sensitive dose threshold there at one gram every four weeks. And we followed that precinct because that research was so strong. So it's nice to feel like we're building on previous studies and then perhaps even detecting another dose threshold with respect to rituximab. And I must say, it was a little bit of a surprise, we came in and saw why is the Liverpool data moving that way and the other one moving this way? So it was a nice data-driven evolution of our multi-variable model. Dr. Justin Abbatemarco: So helpful. And I'll ask everyone to come back for the final episode, where we try to put this all together. We're going to put Ben on the spot and really understand how he approaches these cases in clinical practice. Ben, thank you. Dr. Benjamin Trewin: Thanks very much, Justin.  

Essential tremor is a progressive neurological condition that causes involuntary shaking, often significantly impairing everyday tasks. For many, the loss of fine motor control means giving up lifelong passions and careers. Even simple actions, like buttoning a shirt, eating, or writing, can become overwhelming, leading to frustration, embarrassment, and a diminished quality of life.  In this episode of Curing with Sound, we speak with Howard Faber, a Michigan-based magician who spent decades entertaining audiences before essential tremor forced him to step away from the stage. Howard discusses his experience with focused ultrasound, a noninvasive treatment that ultimately transformed his condition.  He reflects on his journey with progressively worsening tremors, the turning point when Medicare approved focused ultrasound treatment, and his life-changing experience undergoing the procedure. Today, Howard has returned to performing, having regained complete control of his hands and his life. Discussion highlights: The Impact of Essential Tremor: Discover how Howard's progressive tremors interfered with his daily life and his beloved magic career, leading to moments of embarrassment and the difficult decision to stop performing. A Life-Changing Procedure: Follow Howard's experience undergoing focused ultrasound treatment at the Cleveland Clinic, from the preparation process to the emotional moment he realized his tremor was completely gone. All patient stories featured on the Curing with Sound podcast are personal accounts of an individual's experience with focused ultrasound treatment. Please be aware that each patient's situation is unique, and outcomes may vary. The information provided in this story should not be considered as medical advice or a guarantee of specific results. It is important to consult with a qualified healthcare provider to discuss your condition and determine the best treatment options for you. The Focused Ultrasound Foundation does not endorse any specific treatment or medical procedure and encourages all patients to seek professional medical guidance tailored to their individual needs. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/  

Fasting is one of the most powerful healing practices in human history—it's free, requires zero equipment, and your body is literally designed for it. But while it sounds simple, there is a wrong way to do it, especially when it comes to the hormonal "engine switch" that happens in the first 24 hours. In this episode, I walk you through exactly what happens in your body during a 3-day fast, from clearing out "zombie cells" to the 60% drop in aging markers. Sponsors: Sunlighten Sauna: https://get.sunlighten.com/axepodcast Manukora Manuka Honey: https://manukora.com/axe Caraway Home: carawayhome.com/drjoshaxe (Use code DRJOSHAXE) for an exclusive discount Watch The Dr. Josh Axe Show every Monday & Thursday on YouTube: ⁠⁠https://www.youtube.com/@drjoshaxe?sub_confirmation=1⁠⁠ 

Featuring Dr. Peter Kowey, Professor of Medicine at Thomas Jefferson UniversityEpisode Summary: Host JR Sparrow shares his personal journey through a recent open-heart surgery — from a routine echocardiogram that revealed a dangerously low ejection fraction (26%), to an emergency transfer to the Cleveland Clinic — and uses his experience as the backdrop for a deep conversation with renowned cardiologist and cardiac electrophysiologist Dr. Peter Kowey.Topics Covered:JR's personal health scare: echocardiogram complications, misdiagnosis, and open-heart surgeryDr. Kowey's 40+ year career in cardiac electrophysiology (heart rhythm disorders)Being the 3rd center in the world to implant a cardioverter-defibrillator (1982)Development of anti-arrhythmic drugs used worldwideMajor advancements in cardiology: ablation techniques, new blood thinners, wearable heart rhythm monitorsThe difference between clinical practice and medical researchChallenges facing the U.S. healthcare system: insurance gaps, prior authorizations, physician burnoutThe case for universal healthcare coverageThe importance of bedside manner and the "10-minute visit" problem in modern medicineAdvice for up-and-coming physicians and residentsDr. Kowey's Latest Publication: A commentary in the American Journal of Medicine on the state of the U.S. healthcare system and the difficulties patients and practitioners face in accessing quality care.Book Recommendation: Failure to Treat by Dr. Peter KoweyAvailable on AmazonWebsite: peterkoway.author.comIncludes interviews, resources, and the full message behind the bookConnect with Dr. Peter Kowey:Website: peterkoway.author.comBook: Failure to Treat on Amazon

Labia fillers are one of those beauty trends that's quietly gaining traction- and chances are, you didn't even know it was something you were supposed to think about.In this episode, I break down what labia fillers actually are, why more people are getting them, and the beauty standards driving the demand. We're getting into the language, the marketing, and the bigger cultural shift behind this idea of "rejuvenation." If you've ever wondered how far beauty standards can go, this episode might change the way you see them.Are. You. Ready?****************Sources & References:Braun, V. (2009). Female genital cosmetic surgery: A critical review. Feminism & Psychology, 19(2), 139–159.Gill, R. (2007). Gender and the Media. Polity Press.Illich, I. (1976). Limits to Medicine: Medical Nemesis: The Expropriation of Health. Pantheon Books.Bordo, S. (1993). Unbearable Weight: Feminism, Western Culture, and the BodyLiao, L. M., Creighton, S. M., & Crouch, N. S. (2005). Female genital appearance: “Normality” unfolds. BJOG: An International Journal of Obstetrics and Gynaecology, 112(5), 643–646.Tiefer, L. (2008). Female Sexual Dysfunction: A Case Study of Disease Mongering. PLoS Medicine, 5(2), e32.American Society of Plastic Surgeons. (2023). Cosmetic Procedure Trends Report.Royal College of Obstetricians and Gynaecologists. (2013). Ethical Considerations in Relation to Female Genital Cosmetic Surgery (FGCS).American Psychological Association. (2007). Report of the APA Task Force on the Sexualization of Girls.Smith, T. P. (2022). The Infantilization of Women and Pedophilic Beauty Standards in Western Culture: A Literature Review. Medium.Cleveland Clinic. (2023). Dermal Fillers: What to Know Before You Get Them.Mayo Clinic. (2023). Dermal Fillers Overview.****************Leave Us a 5* Rating, it helps the show!Apple Podcast:https://podcasts.apple.com/us/podcast/beauty-unlocked-the-podcast/id1522636282Spotify Podcast:https://open.spotify.com/show/37MLxC8eRob1D0ZcgcCorA****************Follow Us on TikTok & Subscribe to our YouTube Channel!YouTube:@beautyunlockedspodcasthourTikTok:tiktok.com/@beautyunlockedthepod****************Intro/Outro Music:“Fame Inc” by Savvier — https://icons8.com/music

George Stark from the Cleveland Clinic reflects on his early training in biochemistry and how several sabbatical leaves sparked pivotal changes in his research trajectory, eventually drawing him to interferon signaling where he helped establish the core principles of the JAK–STAT pathway and uncovered interesting roles for interferon signaling in cancer. Host: Cindy Leifer Guest: George Stark Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Stark lab Development of the Northern blotting technique (PNAS, 1977) Development of Western blotting for proteins (PNAS, 1979) Discovery of Tyk2 as a critical kinase in interferon response (Cell, 1992) Topical PALA treatment for non-melanoma skin cancer (Exp Dermatol, 2023) Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.

In this week's episode we interview Kinanah Yaseen, MD, a rheumatologist from Cleveland Clinic's department of rheumatic and immunologic diseases about using ultrasound for giant cell arteritis. ·        Intro by Adam J. Brown, MD 0:12 ·        Dr. Brown's recent patient 1:34 ·        History of ultrasound and GCA 3:20 ·        Episode overview 7:05 ·        History of echolocation; how bats helped us invent ultrasound 8:00 ·        What is a bat bomb? 14:56 ·        How the Titanic helped us invent ultrasound 16:48 ·        Neurologists bring ultrasound to medicine 20:09 ·        OB/GYN is next to use ultrasound 23:11 ·        Ultrasound image quality becomes better 26:32 ·        Ultrasound use in giant cell arteritis 28:44 ·        Welcome Kinanah Yaseen, MD 33:49 ·        Using ultrasound in the clinic 34:25 ·        Can you walk us through an ultrasound of the axillary and vertebral arteries? 37:16 ·        Can you tell us why we stopped looking for sites to biopsy by finding narrowing of the vessels?  38:19 ·        Tell us about the halo sign 39:10 ·        How do you validate your ultrasound skills? 40:20 ·        If we start a patient on steroids, how useful is an ultrasound? 42:35 ·        Episode summary 44:20 ·        Thank you for listening 45:57 We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. Kinanah Yaseen, MD, is a is a staff member of Cleveland Clinic's department of rheumatic and immunologic diseases. References: Friedman, G, et al.Isr J Med Sci. 1988 Kaproth-Joslin K A, et al. Radiographics. 2015 ;doi:10.1148/rg.2015140300 Puéchal X, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)92626-7 Schmidt W A, et al. Lancet. 1995;doi:10.1016/s0140-6736(95)93005-1 Sigel B. Ultrasound Med Biol. 1998;doi:10.1016/s0301-5629(97)00264-0 Editor's Note: This has been updated to include references.

Braid is known for his work in hypnotism. But he was also a surgeon with a reputation for pioneering new treatments before he became fascinated with the scientific underpinnings of mesmerism. Research: Braid, James, and Arthur Edward Waite, ed. “Braid on hypnotism. Neurypnology; or, The rationale of nervous sleep considered in relation to animal magnetism or mesmerism and illustrated by numerous cases of its successful application in the relief and cure of disease.” London. George Redway. 1899. https://archive.org/details/braidonhypnotism00brai/page/n7/mode/2up “Clubfoot.” Cleveland Clinic. July 6, 2023. https://my.clevelandclinic.org/health/diseases/16889-clubfoot Crabtree A. “1784: The Marquis de Puységur and the psychological turn in the west.” J Hist Behav Sci.2019;55:199–215. https://doi.org/10.1002/jhbs.21974 Fletcher, George. “James Braid Of Manchester.” The British Medical Journal, vol. 2, no. 3590, 1929, pp. 776–77. JSTOR, http://www.jstor.org/stable/25334090 Hull, Clark L. “Hypnotism in Scientific Perspective.” The Scientific Monthly, vol. 29, no. 2, 1929, pp. 154–62. JSTOR, http://www.jstor.org/stable/14677 “Hypnotism.” Yorkville Enquirer. Feb. 23, 1860. https://www.newspapers.com/image/339341468/?match=1&terms=James%20Braid Lafontaine’s Third Conversazione on Mesmerism.” The Manchester Times and Manchester and Salford Advertiser and Chronicle. Nov. 20, 1841. https://www.newspapers.com/image/406088965/?match=1&terms=lafontaine Loudon, I. “Why are (male) surgeons still addressed as Mr?.” BMJ (Clinical research ed.) 321,7276 (2000): 1589-91. doi:10.1136/bmj.321.7276.1589 Macklis, R M. “Magnetic healing, quackery, and the debate about the health effects of electromagnetic fields.” Annals of internal medicine 118,5 (1993): 376-83. doi:10.7326/0003-4819-118-5-199303010-00009 Martin, Christy. “Mesmerized.” Science History Institute. Dec. 6, 2011. https://www.sciencehistory.org/stories/magazine/mesmerized/ Bramwell, J. Milne. “Hypnotism and treatment by suggestion.” New York. Da Capo Press. 1982. Accessed online: https://archive.org/details/hypnotismandtre00bramgoog/page/n6/mode/1up Rouse, Tyler. “The brief and strange history of mesmerism and surgery.” Hektoen International. Winter 2019. https://hekint.org/2018/12/24/the-brief-and-strange-history-of-mesmerism-and-surgery/ Sandby, George. “Mesmerism and its opponents.” London. Longman, Brown, Green and Longmans. 1848. https://archive.org/details/mesmerismandits01sandgoog “Sudden Death of Mr. James Braid, Surgeon.” The Guardian. March 26, 1860. https://www.newspapers.com/image/257847287/?match=1&terms=James%20Braid Weidow, Brandy, M.S. “James Braid.” Ebsco. 2024. https://www.ebsco.com/research-starters/health-and-medicine/james-braid Yeates, Lindsay Bertram. “James Braid: Surgeon, Gentleman Scientist, and Hypnotist.” University of New South Wales, Sydney. 2013. https://unsworks.unsw.edu.au/entities/publication/7573cb34-ceb9-41bb-a8b1-0951e93fdd10 See omnystudio.com/listener for privacy information.

Émile Coué genuinely seems to have wanted to help people by teaching them how to plant helpful directives in their subconscious minds. Whether he was effective is something that's still debated. Research: Baldwin, J. Mark, et al. “A Disclaimer.” Science, vol. 12, no. 309, 1900, pp. 850–850. JSTOR, http://www.jstor.org/stable/1629542 Baudouin, Charles. “Émile Coué and His Life’s Work.” American Library Service. New York. 1923. https://digirepo.nlm.nih.gov/ext/dw/55330740R/PDF/55330740R.pdf Baudouin, Charles. “Suggestion and Autosuggestion.” New York. Dodd, Mead and Company, 1921. https://dn720207.ca.archive.org/0/items/suggestionauto00bauduoft/suggestionauto00bauduoft.pdf Britannica Editors. "Émile Coué". Encyclopedia Britannica, 22 Feb. 2026, https://www.britannica.com/biography/Emile-Coué “Coue, After Goodby Lecture, Flees City.” Boston Globe. January 31, 1923. https://www.newspapers.com/image/430295545/ “Coue Explains How to Use Auto-Suggestion.” Boston Globe. January 7, 1923. https://www.newspapers.com/image/430953338/?match=1&terms=Coue COUÉ, EMILE. “SELF MASTERY THROUGH CONSCIOUS AUTOSUGGESTION.” AMERICAN LIBRARY SERVICE PUBLISHERS. NEW YORK. 1922. https://www.gutenberg.org/files/27203/27203-h/27203-h.htm “Delirium Tremens.” Cleveland Clinic. June 5, 2023. https://my.clevelandclinic.org/health/diseases/25052-delirium-tremens “EMILE COUÉ DEAD; A MENTAL HEALER; Many Made Well by Saying ‘Every Day, in Every Way, I'm Growing Better and Better.’” New York Times. July 3, 1926. https://www.nytimes.com/1926/07/03/archives/emile-Coué-dead-a-mental-healer-many-made-well-by-saying-every-day.html Heid, Markham. “Is Hypnosis Real? Here’s What Science Says.” Time. March 2, 2023. https://time.com/5380312/is-hypnosis-real-science/ Myga, Kasia A et al. “Autosuggestion: a cognitive process that empowers your brain?.” Experimental brain research 240,2 (2022): 381-394. doi:10.1007/s00221-021-06265-8 Neal, E. Virgil, ed. “Hypnotism and hypnotic suggestion. A scientific treatise on the uses and possibilities of hypnotism, suggestion and allied phenomena.” New York State Publishing Company. Rochester, NY. 1906. https://archive.org/details/hypnotismhypnoti00roch/page/n9/mode/1up “Pliny 1813 Years Ahead of Coue … “ Boston Globe. January 30, 1923. https://www.newspapers.com/image/430295455/?match=1&terms=Coue Rapp, Dean R. “‘Better and Better—’ Couéism as a Psychological Craze of the Twenties in England.” Studies in Popular Culture, vol. 10, no. 2, 1987, pp. 17–36. JSTOR, http://www.jstor.org/stable/23413989 Sage, X. Lamotte. “Hypnotism As It Is: A Book for Everybody.” New York State Publishing Company. Rochester, NY. 1900. Accessed online: https://upload.wikimedia.org/wikipedia/commons/5/5b/Hypnotism_as_it_is%3B_a_book_for_everybody_%28IA_hypnotismasitisb00sage%29.pdf Sari, N. K. et al.“The role of autosuggestion in geriatric patients’ quality of life: a study on psycho-neuro-endocrine-immunology pathway.” Social Neuroscience, 12(5), pp. 551–559. 2017. doi: 10.1080/17470919.2016.1196243 Schlamann, Marc et al. “Autogenic training alters cerebral activation patterns in fMRI.” The International journal of clinical and experimental hypnosis 58,4 (2010): 444-56. doi:10.1080/00207144.2010.499347 Whiteside, Thomas. “Better and Better.” The New Yorker. May 9, 1953. https://www.newyorker.com/magazine/1953/05/16/better-and-better Yeates, Lindsay B. “Émile Coué and his Method (I): The Chemist of Thought and Human Action.” Australian Journal of Clinical Hypnotherapy & Hypnosis, Volume 38, No.1, (Autumn 2016), pp.3-27. https://www.researchgate.net/publication/374753633_Emile_Coue_and_his_Method_I_The_Chemist_of_Thought_and_Human_Action See omnystudio.com/listener for privacy information.